U.S. patent application number 11/890554 was filed with the patent office on 2008-03-13 for fibronectin derivative fc fusions.
Invention is credited to Robert G. Kuimelis, Dasa Lipovsek, Richard W. Wagner.
Application Number | 20080063651 11/890554 |
Document ID | / |
Family ID | 34139775 |
Filed Date | 2008-03-13 |
United States Patent
Application |
20080063651 |
Kind Code |
A1 |
Lipovsek; Dasa ; et
al. |
March 13, 2008 |
Fibronectin derivative Fc fusions
Abstract
Disclosed herein are proteins that include an immunoglobulin
fold and that can be used as scaffolds. Also disclosed herein are
nucleic acids encoding such proteins and the use of such proteins
in diagnostic methods and in methods for evolving novel
compound-binding species and their ligands.
Inventors: |
Lipovsek; Dasa; (Cambridge,
MA) ; Wagner; Richard W.; (Concord, MA) ;
Kuimelis; Robert G.; (Brighton, MA) |
Correspondence
Address: |
ROPES & GRAY LLP;PATENT DOCKETING 39/41
ONE INTERNATIONAL PLACE
BOSTON
MA
02110-2624
US
|
Family ID: |
34139775 |
Appl. No.: |
11/890554 |
Filed: |
August 6, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11483918 |
Jul 7, 2006 |
|
|
|
11890554 |
Aug 6, 2007 |
|
|
|
10728078 |
Dec 3, 2003 |
7115396 |
|
|
11483918 |
Jul 7, 2006 |
|
|
|
09688566 |
Oct 16, 2000 |
|
|
|
10728078 |
Dec 3, 2003 |
|
|
|
09515260 |
Feb 29, 2000 |
6818418 |
|
|
09688566 |
Oct 16, 2000 |
|
|
|
09456693 |
Dec 9, 1999 |
|
|
|
09515260 |
Feb 29, 2000 |
|
|
|
60111737 |
Dec 10, 1998 |
|
|
|
Current U.S.
Class: |
424/176.1 ;
514/19.1; 514/7.7; 514/9.3 |
Current CPC
Class: |
C07K 2317/22 20130101;
C07K 16/00 20130101; C12Q 1/00 20130101; C07K 14/525 20130101; C07K
16/241 20130101; C07K 14/47 20130101; C07K 14/78 20130101; C07K
2318/20 20130101; C40B 40/02 20130101; C07K 2319/00 20130101; C07K
2319/30 20130101; C12N 15/1037 20130101 |
Class at
Publication: |
424/176.1 ;
514/002 |
International
Class: |
A61K 39/395 20060101
A61K039/395; A61K 38/02 20060101 A61K038/02 |
Claims
1. A pharmaceutical composition comprising a therapeutic protein
comprising a tenth domain of fibronectin type III (.sup.10Fn3) and
a physiologically acceptable carrier, wherein the .sup.10Fn3
domain: (a) has at least one loop with a modified amino acid
sequence relative to the sequence of the corresponding loop of a
human .sup.10Fn3 domain, the loop selected from the group of the BC
loop, the DE loop and the FG loop; and (b) binds to a target
compound that is not bound by the corresponding human .sup.10Fn3
domain; wherein the therapeutic protein further comprises an Fc
region of an antibody, and wherein the pharmaceutical composition
is substantially free of endotoxin.
2. The pharmaceutical composition of claim 1, wherein the
.sup.10Fn3 domain has at least two loops with a modified amino acid
sequence relative to the sequence of the corresponding loop of a
human .sup.10Fn3 domain.
3. The pharmaceutical composition of claim 1, wherein the
.sup.10Fn3 domain has at least three loops with a modified amino
acid sequence relative to the sequence of the corresponding loop of
a human .sup.10Fn3 domain.
4. The pharmaceutical composition of claim 1, wherein at least one
of the modified loops in the .sup.10Fn3 domain is extended in
length relative to the corresponding loop of a human .sup.10Fn3
domain.
5. The pharmaceutical composition of claim 1, wherein the DE loop
is extended by 10-13 amino acid residues relative to the
corresponding loop of a human .sup.10Fn3 domain.
6. The pharmaceutical composition of claim 1, wherein the integrin
binding motif, RGD, of the .sup.10Fn3 domain is replaced by an
amino acid sequence as follows: basic amino acid-neutral amino
acid-acidic amino acid.
7. The pharmaceutical composition of claim 1, wherein the Fc region
is an IgG constant region.
8. The pharmaceutical composition of claim 1, wherein the
.sup.10Fn3 domain binds with a K.sub.D of 500 nM or less to the
target compound.
9. The pharmaceutical composition of claim 1, wherein the
.sup.10Fn3 domain binds with a K.sub.D of 10 nM or less to the
target compound.
10. The pharmaceutical composition of claim 1, wherein the
.sup.10Fn3 domain contains no free sulfhydryl moieties and no
disulfide bonds.
11. The pharmaceutical composition of claim 1, wherein the
.sup.10Fn3 domain has an amino acid sequence that is at least 70%
identical to the sequence of a human .sup.10Fn3 domain.
12. The pharmaceutical composition of claim 1, wherein the at least
one modified loop is randomized.
13. The pharmaceutical composition of claim 11, wherein the
.sup.10Fn3 domain is identified by a screening method comprising:
(i) contacting the target compound with a candidate polypeptide
having an .sup.10Fn3 domain comprising at least one randomized loop
under conditions that allow target compound-polypeptide complex
formation; and (ii) obtaining the polypeptide which binds to the
compound.
14. The pharmaceutical composition of claim 13, wherein the
screening method further comprises: (iii) repeating (i) and (ii)
using a further randomized .sup.10Fn3 domain.
15. A pharmaceutical composition comprising a protein comprising a
tenth domain of fibronectin type III (.sup.10Fn3) and a
physiologically acceptable carrier, wherein the .sup.10Fn3 domain:
(a) has 5 or more amino acid changes from the amino acid sequence
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKS
TATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (b) binds to a target
compound that is not bound by the corresponding human .sup.10Fn3
domain; wherein the protein further comprises an Fc region of an
antibody, and wherein the pharmaceutical composition is
substantially free of endotoxin.
16. The pharmaceutical composition of claim 15, wherein the
.sup.10Fn3 domain has 10 or more amino acid changes from the amino
acid sequence TABLE-US-00005
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTV
PGSKSTATISGLKPGVDYTITVYAVTGRGDSPASSKPISTNYRT.
17. A pharmaceutical composition comprising a protein comprising a
tenth domain of fibronectin type III (.sup.10Fn3) and a
physiologically acceptable carrier, wherein the .sup.10Fn3 domain:
(a) is at least 70% identical to amino acid sequence
VSDVPRDLEVVAATPTSLLISWDAPAVTVRYYRITYGETGGNSPVQEFTVPGSKS
TATISGLKPGVDYTITVYAVTGRGDSPASSKPISINYRT (b) binds to a target
compound that is not bound by the corresponding human .sup.10Fn3
domain; wherein the protein further comprises an Fc region of an
antibody, and wherein the pharmaceutical composition is
substantially free of endotoxin.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/483,918, filed Jul. 7, 2006, which is a
continuation of U.S. patent application Ser. No. 10/728,078, filed
Dec. 3, 2003, which is a continuation of U.S. patent application
Ser. No. 09/688,566, filed Oct. 16, 2000, which is a
continuation-in-part of U.S. patent application Ser. No.
09/515,260, filed Feb. 29, 2000, now U.S. Pat. No. 6,818,418, which
is a continuation-in-part of U.S. patent application Ser. No.
09/456,693, filed Dec. 9, 1999, now abandoned, which claims the
benefit of U.S. Provisional application 60/111,737, filed Dec. 10,
1998.
BACKGROUND OF THE INVENTION
[0002] This invention relates to protein scaffolds useful, for
example, for the generation of products having novel binding
characteristics.
[0003] Proteins having relatively defined three-dimensional
structures, commonly referred to as protein scaffolds, may be used
as reagents for the design of engineered products. These scaffolds
typically contain one or more regions which are amenable to
specific or random sequence variation, and such sequence
randomization is often carried out to produce libraries of proteins
from which desired products may be selected. One particular area in
which such scaffolds are useful is the field of antibody
design.
[0004] A number of previous approaches to the manipulation of the
mammalian immune system to obtain reagents or drugs have been
attempted. These have included injecting animals with antigens of
interest to obtain-mixtures of polyclonal antibodies rdactive
against specific antigens, production of monoclonal antibodies in
hybridoma cell culture (Koehler and Milstein, Nature 256:495,
1975), modification of existing monoclonal antibodies to obtain new
or optimized recognition properties, creation of novel antibody
fragments with desirable binding characteristics, and randomization
of single chain antibodies (created by connecting the variable
regions of the heavy and light chains of antibody molecules with a
flexible peptide linker) followed by selection for antigen binding
by phage display (Clackson et al., Nature 352:624, 1991).
[0005] In addition, several non-immunoglobulin protein scaffolds
have been proposed for obtaining proteins with novel binding
properties. For example, a "minibody" scaffold, which is related to
the immunoglobulin fold, has been designed by deleting three beta
strands from a heavy chain variable domain of a monoclonal antibody
(Tramontano et al., J. Mol. Recognit. 7:9, 1994). This protein
includes 61 residues and can be used to present two hypervariable
loops. These two loops have been randomized and products selected
for antigen binding, but thus far the framework appears to have
somewhat limited utility due to solubility problems. Another
framework used to display loops has been tendamistat, a 74 residue,
six-strand beta sheet sandwich held together by two disulfide bonds
(McConnell and Hoess, J. Mol. Biol. 250:460, 1995). This scaffold
includes three loops, but, to date, only two of these loops have
been examined for randomization potential.
[0006] Other proteins have been tested as frameworks and have been
used to display randomized residues on alpha helical surfaces (Nord
et al., Nat. Biotechnol. 15:772, 1997; Nord et al., Protein Eng.
8:601, 1995), loops between alpha helices in alpha helix bundles
(Ku and Schultz, Proc. Natl. Acad. Sci. USA 92:6552, 1995), and
loops constrained by disulfide bridges, such as those of the small
protease inhibitors Markland et al., Biochemistry 35:8045, 1996;
Markland et al., Biochemistry 35:8058, 1996; Rottgen and Collins,
Gene 164:243, 1995; Wang et al., J. Biol. Chem. 270:12250,
1995).
SUMMARY OF THE INVENTION
[0007] The present invention provides a new family of proteins
capable of evolving to bind any compound of interest. These
proteins, which generally make use of a scaffold derived from a
fibronectin type III (Fn3) or Fn3-like domain, function in a manner
characteristic of natural or engineered antibodies (that is,
polyclonal, monoclonal, or single-chain antibodies) and, in
addition, possess structural advantages. Specifically, the
structure of these antibody mimics has been designed for optimal
folding, stability, and solubility, even under conditions that
normally lead to the loss of structure and function in
antibodies.
[0008] These antibody mimics may be utilized for the purpose of
designing proteins which are capable of binding to virtually any
compound (for example, any protein) of interest. For example, the
.sup.10Fn3-based molecules described herein may be used as
scaffolds which are subjected to directed evolution to form a
population with one or more randomized Fn3 loops that are analogous
by position and structure to the complementarity-determining
regions (CDRs) of an antibody variable region, and/or to randomize
Fn3's other three solvent exposed loops. Such a directed evolution
approach results in the production of antibody-like molecules with
high affinities for antigens of interest. In addition, the
scaffolds described herein may be used to display defined exposed
loops (for example, loops previously randomized and selected on the
basis of antigen binding) in order to direct the evolution of
molecules that bind to such introduced loops. A selection of this
type may be carried out to identify recognition molecules for any
individual CDR-like loop or, alternatively, for the recognition of
two or all three CDR-like loops combined into a non-linear
epitope.
[0009] Accordingly, in a first aspect, the present invention
features randomized or mutated scaffold proteins. In particular,
the invention features a non-antibody protein including a domain
having an immunoglobulin-like fold, the non-antibody protein
deriving from a reference protein by having a mutated amino acid
sequence, wherein the non-antibody protein binds with a Kd at least
as tight as 1 .mu.M to a compound that is not bound as tightly by
the reference protein.
[0010] In addition, the invention features a non-antibody protein
deriving from a scaffold protein including a domain having an
immunoglobulin-like fold, wherein the amino acid sequence of the
domain in the derived protein is more than 50% identical to the
amino acid sequence of the domain in the scaffold protein.
[0011] In yet another embodiment, the invention features a protein
that includes a fibronectin type III domain having at least one
randomized loop, the protein being characterized by the ability of
the Fn3 domain to bind to a compound that is not bound by the
corresponding naturally-occurring Fn3 domain.
[0012] In various preferred embodiments, any of these proteins of
the invention bind to their target compounds with a Kd at least as
tight as 500 nM, preferably, with a Kd at least as tight as 100 nM
or 10 nM, and, more preferably, with a Kd at least as tight as 1
nM, 500 pM, 100 pM, or even 20 pM. The protein preferably contains
one, two, or three mutated loops and at least one of the loops, and
preferably two or all three of the loops, contributes to the
binding of the protein to the compound. Additionally, the reference
protein preferably lacks disulfide bonds, and the derivative
protein may have at least one disulfide bond.
[0013] With respect to certain embodiments, the domain having an
immunoglobulinlike fold preferably has a molecular mass less than
10 kD or greater than 7.5 kD, and, more preferably, has a molecular
mass between 7.5-10 kD. The proteins of the invention may be
monomers under physiological conditions or may be multimers, for
example, dimers. In other preferred embodiments, the reference
protein used to derive a mutated protein of the invention is a
naturally-Qccurring mammalian protein (for example, a human
protein); and the domain having an immunoglobulin-like fold is
mutated and includes up to 50%, and preferably up to 34%, mutated
amino acids as compared to the immunoglobulin-like fold of the
reference protein. In addition, the domain having the
immunoglobulin-like fold preferably consists of approximately
50-150 amino acids, and more preferably consists of approximately
50 amino acids.
[0014] Derivative proteins of the invention may be derived from any
appropriate reference protein including, but not limited to, the
preferred proteins, fibronectin or a fibronectin dimer, tenascin,
N-cadherin, E-cadherin, ICAM, titin, GCSF-receptor, cytokine
receptor, glycosidase inhibitor, antibiotic chromoprotein, myelin
membrane adhesion molecule PO, CD8, CD4, CD2, class I MHC, T-cell
antigen receptor, CD 1, C2 and I-set domains of VCAM-1, I-set
immunoglobulin domain of myosin-binding protein C, 1-set
immunoglobulin domain of myosin-binding protein H, 1-set
immunoglobulin domain of telokin, NCAM, twitchin, neuroglian,
growth hormone receptor, erythropoietin receptor, prolactin
receptor, interferon-gamma receptor,
.beta.-galactosidase/glucuronidase, .beta.-glucuronidase,
transglutaminase, T-cell antigen receptor, superoxide dismutase,
tissue factor domain, cytochrome F, green fluorescent protein,
GroEL, and thaumatin.
[0015] In further preferred embodiments of Fn3 domain-containing
proteins, the fibronectin type III domain is a mammalian (for
example, a human) fibronectin type III domain; and the protein
includes the tenth module of the fibronectin type III (.sup.10Fn3)
domain. In such proteins, compound binding is preferably mediated
by either one, two, or three .sup.10Fn3 loops. In other preferred
embodiments, the second (DE) loop of .sup.10Fn3 may be extended in
length relative to the naturally-occurring module, or the
.sup.10Fn3 may lack an integrin-binding motif. In these molecules,
the integrin-binding motif may be replaced by an amino acid
sequence in which a polar amino acid-neutral amino acid-acidic
amino acid sequence (in the N-terminal to C-terminal direction)
replaces the integrin-binding motif; alternatively, one preferred
sequence is serine-glycine-glutamate. In another preferred
embodiment, the fibronectin type III domain-containing proteins of
the invention lack disulfide bonds.
[0016] Any of the proteins of the invention (for example, the
fibronectin type III domain-containing proteins) may be formulated
as part of a fusion protein. If the fusion protein is to be used
for compound binding or compound binding selections, the fusion
protein includes a heterologous protein that does not itself bind
to the compound of interest. The heterologous protein may, for
example, be an antibody or antibody domain (such as an
immunoglobulin F.sub.c domain), a complement protein, a toxin
protein, or an albumin protein. In addition, any of the proteins of
the invention (for example, the fibronectin type III domain
proteins) may be covalently bound to a nucleic acid (for example,
an RNA), and the nucleic acid may encode the protein. Moreover, the
protein may be a multimer, or, particularly if it lacks an
integrin-binding motif, it may be formulated in a
physiologically-acceptable carrier.
[0017] The present invention also features proteins that include a
fibronectin type III domain having at least one mutation in a
.beta.-sheet sequence. Again, these proteins are characterized by
their ability to bind to compounds that are not bound or are not
bound as tightly by the corresponding naturally-occurring
fibronectin domain.
[0018] Any of the proteins of the invention may be immobilized on a
solid support (for example, a bead or chip), and these proteins may
be arranged in any configuration on the solid support, including an
array.
[0019] In a related aspect, the invention further features nucleic
acids encoding any of the proteins of the invention. In preferred
embodiments, the nucleic acid is DNA or RNA.
[0020] In another related aspect, the invention also features a
method for generating a protein which includes a fibronectin type
III domain and which is pharmaceutically acceptable to a mammal,
involving removing the integrin-binding domain of said fibronectin
type III domain. This method may be applied to any of the
fibronectin type III domain-containing proteins described above and
is particularly useful for generating proteins for human
therapeutic applications. The invention also features such
fibronectin type III domain-containing proteins which lack
integrin-binding domains.
[0021] In yet another related aspect, the invention features
methods of obtaining derivative non-antibody proteins which bind to
compounds of interest. One such method involves: (a) providing a
non-antibody scaffold protein including an immunoglobulin-like
fold, wherein the scaffold protein does not bind to the compound
with a Kd as tight as 1 .mu.M; (b) generating mutated derivatives
of the non-antibody scaffold protein, thereby producing a library
of mutated proteins; (c) contacting the library with the compound;
(d) selecting from the library at least one derivative protein
which binds to the compound with a Kd at least as tight as 1 .mu.M;
and (e) optionally repeating steps (b)-(d) substituting for the
non-antibody scaffold protein in repeated step (b) the product from
the previous step (d). This technique may also be carried out with
any of the proteins of the invention (for example, any of the
fibronectin type III domain-containing proteins).
[0022] In yet other related aspects, the invention features
screening methods which may be used to obtain or evolve randomized
or mutated proteins of the invention capable of binding to
compounds of interest, or to obtain or evolve compounds (for
example, proteins) capable of binding to a particular protein
containing a randomized or mutated motif. In addition, the
invention features screening procedures which combine these two
methods, in any order, to obtain either compounds or proteins of
interest.
[0023] In particular, a first screening method, useful for the
isolation or identification of randomized or mutated proteins of
interest, involves: (a) contacting a compound of interest with a
candidate protein, the candidate protein being a derivative
non-antibody protein including a domain having an
immunoglobulin-like fold, the non-antibody protein deriving from a
reference protein by having a mutated amino acid sequence wherein
the non-antibody protein binds with a Kd at least as tight as 1
.mu.M to a compound that is not bound as tightly by the reference
protein, wherein the contacting is carried out under conditions
that allow compound-protein complex formation; and (b) obtaining,
from the complex, the derivative protein that binds to the
compound. This general technique may also be carried out with a
fibronectin type III domain protein having at least one randomized
or mutated loop.
[0024] The second screening method is for isolating or identifying
a compound which binds to a protein of the invention. This method
begins with a non-antibody protein including a domain having an
immunoglobulin-like fold and deriving from a reference protein by
having a mutated amino acid sequence, wherein the non-antibody
protein binds with a Kd at least as tight as 1 .mu.M to a compound
that is not bound as tightly by the reference protein. This
derivative protein is then contacted with a candidate compound,
wherein the contacting is carried out under conditions that allow
compound-protein complex formation, and the compound which binds to
the derivative protein is obtained from the complex. Again, this
general technique may be carried out with any protein of the
invention, for example, a protein with a mutated fibronectin type
III domain.
[0025] In addition, the invention features diagnostic methods which
employ the proteins of the invention (for example, fibronectin type
III scaffold proteins and their derivatives). Such diagnostic
methods may be carried out on a sample (for example, a biological
sample) to detect one analyte or to simultaneously detect many
different analytes in the sample. The method may employ any of the
scaffold molecules described herein. Preferably, the method
involves (a) contacting the sample with a protein of the invention
that binds to the compound analyte, the contacting being carried
out under conditions that allow compound-protein complex formation;
and (b) detecting the complex, and therefore the compound in the
sample. In addition, this method may be used to quantitate, as well
as detect, compound levels in a sample.
[0026] In preferred embodiments of any of the selection or
diagnostic methods described herein, the protein of the invention
binds to its target compound with a Kd at least as tight as 1 .mu.M
or 500 nM, preferably, with a Kd at least as tight as 100 nM or 10
nM, and, more preferably, with a Kd at least as tight as 1 nM, 500
.mu.M, 100 .mu.M, or even 20 .mu.M. The protein preferably contains
one, two, or three mutated loops and at least one of the loops, and
preferably two or all three of the loops contributes to the binding
of the protein to the compound. Additionally, the reference protein
preferably lacks disulfide bonds, and the derivative protein may
have at least one disulfide bond.
[0027] With respect to certain embodiments of the methods, the
domain having an immunoglobulin-like fold preferably has a
molecular mass less than 10 kD or greater than 7.5 kD, and, more
preferably, has a molecular mass between 7.5-10 kD. The proteins of
the invention may be monomers under physiological conditions or may
be multimers, for example, dimers. In other preferred embodiments,
the reference protein used to derive a mutated protein of the
invention is a naturally-occurring mammalian protein (for example,
a human protein); and the domain having an immunoglobulin-like fold
is mutated and includes up to 50%, and preferably up to 34%,
mutated amino acids as compared to the immunoglobulin-like fold of
the reference protein. In addition, the domain having an
immunoglobulin-like fold preferably consists of approximately
50-150 amino acids, and more preferably consists of approximately
50 amino acids.
[0028] Derivative proteins used in the methods of the invention may
be derived from any appropriate reference protein including, but
not limited to, the preferred proteins, fibronectin or a
fibronectin dimer, tenascin, N-cadherin, E-cadherin, ICAM, titin,
GCSF-receptor, cytokine receptor, glycosidase inhibitor, antibiotic
chromoprotein, myelin membrane adhesion molecule PO, CD8, CD4, CD2,
class I MHC, T-cell antigen receptor, CD1, C2 and I-set domains of
VCAM-1,1-set immunoglobulin domain of myosin-binding protein C,
1-set immunoglobulin domain of myosin-binding protein H, I-set
immunoglobulin domain of telokin, NCAM, twitchin, neuroglian,
growth hormone receptor, erythropoietin receptor, prolactin
receptor, interferon-gamma receptor,
.beta.-galactosidase/glucuronidase, .beta.-glucuronidase,
transglutaminase, T-cell antigen receptor, superoxide dismutase,
tissue factor domain, cytochrome F, green fluorescent protein,
GroEL, and thaumatin.
[0029] In addition, the steps of the selection methods described
herein may be repeated with further mutation or randomization being
carried out between cycles. For example, for the methods involving
a protein having a mutated or randomized fibronectin type III
domain, at least one loop of the fibronectin type III domain of the
protein obtained in step (b) may be mutated and steps (a) and (b)
repeated using the further randomized protein, or the compound
obtained in step (b) may be modified and steps (a) and (b) repeated
using the further modified compound. In these methods, the compound
is preferably a protein, and the fibronectin type III domain is
preferably a mammalian (for example, a human) fibronectin type III
domain. In other preferred embodiments, the protein includes the
tenth module of the fibronectin type III domain (.sup.10Fn3), and
binding is mediated by one, two, or three .sup.10Fn3 loops. In
addition, the second (DE) loop of .sup.10Fn3 may be extended in
length relative to the naturally-occurring module, or .sup.10Fn3
may lack an integrin-binding motif. Again, as described above, the
integrin-binding motif may be replaced by an amino acid sequence in
which a basic amino acid-neutral amino acid-acidic amino acid
sequence (in the N-terminal to C-terminal direction) replaces the
integrin-binding motif; alternatively, one preferred replacement
sequence is serine-glycine-glutamate.
[0030] The selection and diagnostic methods described herein may be
carried out using any of the proteins of the invention (for
example, a fibronectin type III domain-containing protein). In
addition, any of these proteins may be formulated as part of a
fusion protein with a heterologous protein (for example, an
antibody or antibody domain (including an immunoglobulin F.sub.c
domain) that does not itself bind the compound of interest, or a
complement protein, toxin protein, or albumin protein). In
addition, selections and diagnostic methods may be carried out
using the proteins of the invention (for example, the fibronectin
type III domain proteins) covalently bound to nucleic acids (for
example, RNAs or any nucleic acid which encodes the protein).
Moreover, the selections and diagnostic methods may be carried out
using these proteins (for example, the fibronectin
domain-containing proteins) as monomers or as multimers, such as
dimers.
[0031] Preferably, the selections and diagnostic methods involve
the immobilization of the binding target on a solid support.
Preferred solid supports include columns (for example, affinity
columns, such as agarose-based affinity columns), microchips, or
beads. Alternatively, the proteins (for example, the Fn3
domain-containing proteins) may be immobilized and contacted with
one or more potential binding targets.
[0032] For the diagnostic methods, the compound is often a protein,
but may also be any other analyte in a sample. Detection may be
accomplished by any standard technique including, without
limitation, radiography, fluorescence detection, mass spectroscopy,
or surface plasmon resonance.
[0033] In a final aspect, the invention features a non-antibody
protein that binds tumor necrosis factor-.alpha. (TNF-.alpha.) with
a Kd at least as tight as 1 .mu.M, the protein having a sequence
that is less than 20% identical to TNF-.alpha. receptor (for
example, a naturally-occurring TNF-.alpha. receptor, such as a
mammalian or human TNF-.alpha. receptor).
[0034] In preferred embodiments, this protein includes a mutated
fibronectin type III domain and the protein is mutated in the DE,
BC, and FG loops. Preferably, the mutated FG loop is the same
length as the wild-type FG loop. In other preferred embodiments,
the protein includes an immunoglobulin-like fold (preferably,
having a molecular mass less than 10 kD, greater than 7.5 kD, or
between 7.5-10 kD) that consists of approximately 50-150 amino
acids, and preferably, approximately 50 amino acids.
[0035] The TNF-.alpha. binders according to the invention bind
TNF-.alpha. with a Kd at least as tight as 1 .mu.M, preferably, at
least as tight as 500 nM, 100 nM, or 10 nM, more preferably, at
least as tight as 1 nM or 500 .mu.M, and, most preferably, at least
as tight as 100 .mu.M or even 20 .mu.M. Preferably, these proteins
contain one, two, or three mutated loops, and at least one, and
preferably two or all three of the loops, contribute to the binding
of the non-antibody protein to TNF-.alpha.. In other preferred
embodiments, the non-antibody protein has at least one disulfide
bond, and the non-antibody protein is a monomer or dimer under
physiological conditions.
[0036] The TNF-.alpha. binders may be immobilized on a solid
support (for example, a chip or bead), and may be part of an array.
In addition, any of the TNF-.alpha. binders may be joined to a
heterologous protein (for example, a heterologous protein that is
an antibody or an antibody domain that does not bind TNF-.alpha.,
an immunoglobulin F.sub.c domain, a complement protein, or an
albumin protein).
[0037] If desired, the protein may include a mutated fibronectin
type III domain (for example, one derived from a human fibronectin
type III domain, such as a mutated tenth module of the fibronectin
type III domain (.sup.10Fn3)). In addition, the protein may lack an
.sup.10Fn3 integrin-binding motif. TNF-.alpha. binders preferably
include a non-naturally occurring sequence in a loop of .sup.10Fn3
(for example, the loop sequence PW(A/G), and may include a
non-naturally occurring sequence in a .beta.-sheet of .sup.10Fn3.
Particularly preferred TNF-.alpha. binders of the invention are
shown in FIG. 25 (SEQ ID NOS: 34-140).
[0038] In addition, in related aspects, the invention features
nucleic acids encoding any of the TNF-.alpha. binding proteins of
the invention, as well as a loop structure on any protein that
includes any one of the amino acid sequences of FIG. 25 (SEQ ID
NOS: 34-140).
[0039] As used herein, by "non-antibody protein" is meant a protein
that is not produced by the B cells of a mammal either naturally or
following immunization of a mammal. This term also excludes
antibody fragments of more than 100 amino acids, preferably, more
than 80 amino acids, and, most preferably, more than 50 amino acids
in length.
[0040] By "immunoglobulin-like fold" is meant a protein domain of
between about 80-150 amino acid residues that includes two layers
of antiparallel beta-sheets, and in which the flat, hydrophobic
faces of the two beta-sheets are packed against each other.
Proteins according to the invention may include several
immunoglobulin-like folds covalently bound or associated
non-covalently into larger-structures.
[0041] By "scaffold" is meant a protein used to select or design a
protein framework with specific and favorable properties, such as
binding. When designing proteins from the scaffold, amino acid
residues that are important for the framework's favorable
properties are retained, while others residues may be varied. Such
a scaffold has less than 50% of the amino acid residues that vary
between protein derivatives having different properties and greater
than or equal to 50% of the residues that are constant between such
derivatives. Most commonly, these constant residues confer the same
overall three-dimensional fold to all the variant domains,
regardless of their properties.
[0042] By "fibronectin type III domain" is meant a domain having 7
or 8 beta strands which are distributed between two beta sheets,
which themselves pack against each other to form the core of the
protein, and further containing loops which connect the beta
strands to each other and are solvent exposed. There are at least
three such loops at each edge of the beta sheet sandwich, where the
edge is the boundary of the protein perpendicular to the direction
of the beta strands. Preferably, a fibronectin type III domain
includes a sequence which exhibits at least 30% amino acid
identity, and preferably at least 50% amino acid identity, to the
sequence encoding the structure of the .sup.10Fn3 domain referred
to as "1ttg" (I)="1ttg" (one ttg)) available from the RCSB
(Research Collaboratory for Structural Bioinformatics) Protein Data
Base. Sequence identity referred to in this definition is
determined by the Homology program, available from Molecular
Simulation (San Diego, Calif.). The invention further includes
polymers of .sup.10Fn3-related molecules, which are an extension of
the use of the monomer structure, whether or not the subunits of
the polyprotein are identical.
[0043] By "naturally occurring" is meant any protein that is
encoded by a living organism.
[0044] By "randomized" or "mutated" is meant including one or more
amino acid alterations relative to a template sequence. By
"randomizing" or "mutating" is meant the process of introducing,
into a sequence, such an amino acid alteration. Randomization or
mutation may be accomplished through intentional, blind, or
spontaneous sequence variation, generally of a nucleic acid coding
sequence, and may occur by any technique, for example, PCR,
error-prone PCR, or chemical DNA synthesis. By a "corresponding,
non-mutated protein" is meant a protein that is identical in
sequence, except for the introduced-amino acid mutations.
[0045] By a "protein" is meant any sequence of two or more amino
acids, regardless of length, post-translation modification, or
function. "Protein" and "peptide" are used interchangeably
herein.
[0046] By "RNA" is meant a sequence of two or more covalently
bonded, naturally occurring or modified ribonucleotides. One
example of a modified RNA included within this term is
phosphorothioate RNA.
[0047] By "DNA" is meant a sequence of two or more covalently
bonded, naturally occurring or modified deoxyribonucleotides.
[0048] By a "nucleic acid" is meant any two or more covalently
bonded nucleotides or nucleotide analogs or derivatives. As used
herein, this term includes, without limitation, DNA, RNA, and
PNA.
[0049] By "pharmaceutically acceptable" is meant a compound or
protein that may be administered to an animal (for example, a
mammal) without significant adverse medical consequences.
[0050] By "physiologically acceptable carrier" is meant a carrier
which does not have a significant detrimental impact on the treated
host and which retains the therapeutic properties of the compound
with which it is administered. One exemplary physiologically
acceptable carrier is physiological saline. Other physiologically
acceptable carriers and their formulations are known to one skilled
in the art and are described, for example, in Remington's
Pharmaceutical Sciences, (18.sup.th edition), ed. A. Gennaro, 1990,
Mack Publishing Company, Easton, Pa., incorporated herein by
reference.
[0051] By a "fusion protein" is meant a protein that includes (i) a
scaffold protein of the invention joined to (ii) a second,
different (i.e., "heterologous") protein. "Fusion proteins" are
distinguished from "nucleic acid-protein fusions" and "RNA-protein
fusions" in that a "fusion protein" is composed entirely of amino
acids, while both a "nucleic acid-protein fusion" and an
"RNA-protein fusion" include a stretch of nucleic acids (the
nucleic acid or RNA component) joined to a stretch of amino acids
(the protein component).
[0052] By "selecting" is meant substantially partitioning a
molecule from other molecules in a population. As used herein, a
"selecting" step provides at least a 2-fold, preferably, at least a
30-fold, more preferably, at least a 100-fold, and, most
preferably, at least a 1000-fold enrichment of a desired molecule
relative to undesired molecules in a population following the
selection step. A selection step may be repeated any number of
times, and different types of selection steps may be combined in a
given approach.
[0053] By "binding partner," as used herein, is meant any molecule
which has a specific, covalent or non-covalent affinity for a
portion of a desired compound (for example, protein) of interest.
Examples of binding partners include, without limitation, members
of antigen/antibody pairs, protein/inhibitor pairs, receptor/ligand
pairs (for example cell surface receptor/ligand pairs, such as
hormone receptor/peptide hormone pairs), enzyme/substrate pairs
(for example, kinase/substrate pairs), lectin/carbohydrate pairs,
oligomeric or heterooligomeric protein aggregates, DNA binding
protein/DNA binding site pairs, RNA/protein pairs, and nucleic acid
duplexes, heteroduplexes, or ligated strands, as well as any
molecule which is capable of forming one or more covalent or
non-covalent bonds (for example, disulfide bonds) with any portion
of another molecule (for example, a compound or protein).
[0054] By a "solid support" is meant, without limitation, any
column (or column material), bead, test tube, microtiter dish,
solid particle (for example, agarose or sepharose), microchip (for
example, silicon, silicon-glass, or gold chip), or membrane (for
example, an inorganic membrane, nitrocellulose, or the membrane of
a liposome or vesicle) to which an antibody mimic or an affinity
complex may be bound, either directly or indirectly (for example,
through other binding partner intermediates such as other
antibodies or Protein A), or in which an antibody mimic or an
affinity complex may be embedded (for example, through a receptor
or channel).
[0055] The present invention provides a number of advantages. For
example, as described in more detail below, the present antibody
mimics exhibit improved biophysical properties, such as stability
under reducing conditions and solubility at high concentrations. In
addition, these molecules may be readily expressed and folded in
prokaryotic systems, such as E. coli in eukaryotic systems, such as
yeast, and in in vitro translation systems, such as the rabbit
reticulocyte lysate system. Moreover, these molecules are extremely
amenable to affinity maturation techniques involving multiple
cycles of selection, including in vitro selection using RNA-protein
fusion technology (Roberts and Szostak, Proc. Natl. Acad. Sci. USA
94:12297, 1997; Szostak et al., U.S. Ser. No. 09/007,005 and U.S.
Ser. No. 09/247,190; Szostak et al. WO98/31700), phage display
(see, for example, Smith and Petrenko, Chem. Rev. 97:317, 1997),
and yeast display systems (see, for example, Boder and Wittrup,
Nature Biotech. 15:553, 1997).
[0056] Other features and advantages of the present invention will
be apparent from the following detailed description thereof, and
from the claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0057] FIG. 1 is a photograph showing a comparison between the
structures of antibody heavy chain variable regions from camel
(dark blue) and llama (light blue), in each of two
orientations.
[0058] FIG. 2 is a photograph showing a comparison between the
structures of the camel antibody heavy chain variable region (dark
blue), the llama antibody heavy chain variable region (light blue),
and a fibronectin type III module number 10 (.sup.10Fn3)
(yellow).
[0059] FIG. 3 is a photograph showing a fibronectin type III module
number 10 (.sup.10Fn3), with the loops corresponding to the
antigen-binding loops in IgG heavy chains highlighted in red.
[0060] FIG. 4 is a graph illustrating a sequence alignment between
a fibronectin type III protein domain and related protein
domains.
[0061] FIG. 5 is a photograph showing the structural similarities
between a .sup.10Fn3 domain and 15 related proteins, including
fibronectins, tenascins, collagens, and undulin. In this
photograph, the regions are labeled as follows: constant, dark
blue; conserved, light blue; neutral, white; variable, red; and RGD
integrin-binding motif (variable), yellow.
[0062] FIG. 6 is a photograph showing space filling models of
fibronectin III modules 9 and 10, in each of two different
orientations. The two modules and the integrin binding loop (RGD)
are labeled. In this figure, blue indicates positively charged
residues, red indicates negatively charged residues, and white
indicates uncharged residues.
[0063] FIG. 7 is a photograph showing space filling models of
fibronectin III modules 7-10, in each of three different
orientiations. The four modules are labeled. In this figure, blue
indicates positively charged residues, red indicates negatively
charged residues, and white indicates uncharged residues.
[0064] FIG. 8 is a photograph illustrating the formation, under
different salt conditions, of RNA-protein-fusions which include
fibronectin type III domains.
[0065] FIG. 9 is a series of photographs illustrating the selection
of fibronectin type III domain-containing RNA-protein fusions, as
measured by PCR signal analysis.
[0066] FIG. 10 is a graph illustrating an increase in the percent
TNF-.alpha. binding during the selections described herein, as well
as a comparison between RNA-protein fusion and free protein
selections.
[0067] FIG. 11 is a series of schematic representations showing
IgG, .sup.10Fn3, Fn-CH.sub.1--CH.sub.2--CH.sub.3, and
Fn-CH.sub.2--CH.sub.3 (clockwise from top left).
[0068] FIG. 12 is a photograph showing a molecular model of
Fn-CH.sub.1--CH.sub.2--CH.sub.3 based on known three-dimensional
structures of IgG (X-ray crystallography) and .sup.10Fn3 (NMR and
X-ray crystallography).
[0069] FIG. 13 is a graph showing the time course of an exemplary
.sup.10Fn3-based nucleic acid-protein fusion selection of
TNF-.alpha. binders. The proportion of nucleic acid-protein fusion
pool (open diamonds) and free protein pool (open circles) that
bound to TNF-.alpha.-Sepharose, and the proportion of free protein
pool (full circles) that bound to underivatized Sepharose, are
shown.
[0070] FIGS. 14 and 15 are graphs illustrating TNF-.alpha. binding
by TNF-.alpha. Fn-binders. In particular, these figures show mass
spectra data obtained from a .sup.10Fn3 fusion chip and non-fusion
chip, respectively.
[0071] FIGS. 16 and 17 are the phosphorimage and fluorescence scan,
respectively, of an .sup.10Fn3 array, illustrating TNF-.alpha.
binding.
[0072] FIG. 18 is a graph showing an alignment of the primary
sequences of the llama V.sub.H domain and the wild-type human
.sup.10Fn3 domain. Homologous residues between the two sequences
are indicated. The .sup.10Fn3 residues outside the randomized loops
that were found to have mutated in approximately 45% of the
selected clones are marked with arrows under the wild-type
.sup.10Fn3 sequence and with the letter that identifies the
selected residue.
[0073] FIG. 19 shows schematic representations of the llama V.sub.H
domain and the wild-type human .sup.10Fn3 domain. The locations of
the mutated framework residues are indicated.
[0074] FIG. 20 is a graph illustrating the efficiency and
specificity of binding of a free-protein pool translated from the
original library (R0) and after ten rounds of selection with
TNF-.alpha. (R10). Protein pool binding to underivatized Sepharose,
to TNF-.alpha.-Sepharose, to IL-1.alpha.-Sepharose, and to
IL-13-Sepharose is compared.
[0075] FIG. 21 is a series of IgG-like scaffolds for the display of
up to three loops.
[0076] FIG. 22 is a series of IgG-like scaffolds for the display of
up to four, or even six, loops.
[0077] FIG. 23 is a series of scaffolds, unrelated to IgG, for the
display of loop structures.
[0078] FIGS. 24A-24D are photographic and graphic illustrations
demonstrating the specific capture of a target (TNF-.alpha.) by a
mimic immobilized on a solid surface.
[0079] FIG. 25 is a graph listing exemplary TNF-.alpha. binders
(SEQ ID NOS: 33-140) according to the invention.
DETAILED DESCRIPTION
[0080] The novel antibody mimics described herein have been
designed to be superior both to antibody-derived fragments and to
non-antibody frameworks, for example, those frameworks cited
above.
[0081] The major advantage of these antibody mimics over antibody
fragments is structural. These antibody mimics are derived from
whole, stable, and soluble structural scaffolds. For example, the
Fn3 scaffold is found in the human body. Consequently, they exhibit
better folding and thermostability properties than antibody
fragments, whose creation involves the removal of parts of the
antibody native fold, often exposing amino acid residues that, in
an intact antibody, would be buried in a hydrophobic environment,
such as an interface between variable and constant domains.
Exposure of such hydrophobic residues to solvent increases the
likelihood of aggregation of the antibody fragments.
[0082] In addition, the scaffolds described herein have no
disulfide bonds, which have been reported to retard or prevent
proper folding of antibody fragments under certain conditions.
Since the present scaffolds do not rely on disulfides for native
fold stability, they are stable under reducing conditions, unlike
antibodies and their fragments which unravel upon disulfide bond
reduction.
[0083] Moreover, these scaffolds provide the functional advantages
of antibody molecules. In particular, despite the fact that the
.sup.10Fn3 module is not an immunoglobulin, its overall fold is
close to that of the variable region of the IgG heavy chain (FIG.
2), making it possible to display the three fibronectin loops
analogous to CDRs in relative orientations similar to those of
native antibodies. Because of this structure, the present antibody
mimics possess antigen binding properties that are similar in
nature and affinity to those of antibodies, and a loop
randomization and shuffling strategy may be employed in vitro that
is similar to the process of affinity maturation of antibodies in
vivo.
[0084] There are now described below exemplary scaffolds, for
example, fibronectin-based scaffolds, and their use for
identifying, selecting, and evolving novel binding proteins as well
as their target ligands. These examples are provided for the
purpose of illustrating, and not limiting, the invention.
.sup.10Fn3 Structural Motif
[0085] Preferred antibody mimics of the present invention are based
on the structure of a fibronectin module of type III (Fn3), a
common domain found in mammalian blood and structural proteins.
This domain occurs more than 400 times in the protein sequence
database and has been estimated to occur in 2% of the proteins
sequenced to date, including fibronectins, tenascin, intracellular
cytoskeletal proteins, and prokaryotic enzymes (Bork and Doolittle,
Proc. Natl. Acad. Sci. USA 89:8990, 1992; Bork et al., Nature
Biotech. 15:553, 1997; Meinke et al., J. Bacteriol. 175:1910, 1993;
Watanabe et al., J. Biol. Chem. 265:15659, 1990). A particular
scaffold is the tenth module of human Fn3 (.sup.10Fn3), which
comprises 94 amino acid residues. The overall fold of this domain
is closely related to that of the smallest functional antibody
fragment, the variable region of the heavy chain, which comprises
the entire antigen recognition unit in camel and llama IgG (FIGS.
1, 2). The major differences between camel and llama domains and
the .sup.10Fn3 domain are that (i) .sup.10Fn3 has fewer beta
strands (seven vs. nine) and (ii) the two beta sheets packed
against each other are connected by a disulfide bridge in the camel
and llama domains, but not in .sup.10Fn3.
[0086] The three loops of .sup.10Fn3 corresponding to the
antigen-binding loops of the IgG heavy-chain run between amino acid
residues 21-31 (BC), 51-56 (DE), and 76-88 (FG) (FIG. 3). The
length of the BC and DE loop, 10 and 6 residues, respectively, fall
within the narrow range of the corresponding antigen-recognition
loops found in antibody heavy chains, that is, 7-10 and 4-8
residues, respectively. Accordingly, once randomized and selected
for high antigen affinity, these two loops may make contacts with
antigens equivalent to the contacts of the corresponding loops in
antibodies.
[0087] In contrast, the FG loop of .sup.10Fn3 is 12 residues long,
whereas the corresponding loop in antibody heavy chains ranges from
4-28 residues. To optimize antigen binding, therefore, the length
of the FG loop of .sup.10Fn3 is preferably randomized in length as
well as in sequence to cover the CDR3 range of 4-28 residues to
obtain the greatest possible flexibility and affinity in antigen
binding. Indeed, in general, the lengths as well as the sequences
of the CDR-like loops of the antibody mimics may be randomized
during in vitro or in vivo affinity maturation (as described in
more detail below).
[0088] The tenth human fibronectin type III domain, .sup.10Fn3,
refolds rapidly even at low temperature; its backbone conformation
has been recovered within 1 second at 5.degree. C. Thermodynamic
stability of .sup.10Fn3 is high (AGu=24 kJ/mol=5.7 kcal/mol),
correlating with its high melting temperature of 110.degree. C.
[0089] One of the physiological roles of .sup.10Fn3 is as a subunit
of fibronectin, a glycoprotein that exists in a soluble form in
body fluids and in an insoluble form in the extracellular matrix
(Dickinson et al., J. Mol. Biol. 236:1079, 1994). A fibronectin
monomer of 220-250 kD contains 12 type I modules, two type II
modules, and 17 fibronectin type III modules (Potts and Campbell,
Curr. Opin. Cell Biol. 6:648, 1994). Different type III modules are
involved in the binding of fibronectin to integrins, heparin, and
chondroitin sulfate. .sup.10Fn3 was found to mediate cell adhesion
through an integrin-binding Arg-Gly-Asp (RGD) motif on one of its
exposed loops. Similar RGD motifs have been shown to be involved in
integrin binding by other proteins, such as fibrinogen, von
Wellebrand factor, and vitronectin (Hynes et al., Cell 69:11,
1992). No other matrix- or cell-binding roles have been described
for .sup.10Fn3.
[0090] The observation that .sup.10Fn3 has only slightly more
adhesive activity than a short peptide containing RGD is consistent
with the conclusion that the cell-binding activity of .sup.10Fn3 is
localized in the RGD peptide rather than distributed throughout the
.sup.10Fn3 structure (Baron et al., Biochemistry 31:2068, 1992).
The fact that .sup.10Fn3 without the RGD motif is unlikely to bind
to other plasma proteins or extracellular matrix makes .sup.10Fn3 a
useful scaffold to replace antibodies. In addition, the presence of
.sup.10Fn3 in natural fibrinogen in the bloodstream suggests that
.sup.10Fn3 itself is unlikely to be immunogenic in the organism of
origin.
[0091] In addition, we have determined that the .sup.10Fn3
framework possesses exposed loop sequences tolerant of
randomization, facilitating the generation of diverse pools of
antibody mimics. This determination was made by examining the
flexibility of the .sup.10Fn3 sequence. In particular, the human
.sup.10Fn3 sequence was aligned with the sequences of fibronectins
from other sources as well as sequences of related proteins (FIG.
4), and the results of this alignment were mapped onto the
three-dimensional structure of the human .sup.10Fn3 domain (FIG.
5). This alignment revealed that the majority of conserved residues
are found in the core of the beta sheet sandwich, whereas the
highly variable residues are located along the edges of the beta
sheets, including the N- and C-termini, on the solvent-accessible
faces of both beta sheets, and on three solvent-accessible loops
that serve as the hypervariable loops for affinity maturation of
the antibody mimics. In view of these results, the randomization of
these three loops are unlikely to have an adverse effect on the
overall fold or stability of the .sup.10Fn3 framework itself.
[0092] For the human .sup.10Fn3 sequence, this analysis indicates
that, at a minimum, amino acids 1-9, 44-50, 61-54, 82-94 (edges of
beta sheets); 19, 21, 3046 (even), 79-65 (odd) (solvent-accessible
faces of both beta sheets); 21-31, 51-56, 76-88 (CDR-like
solvent-accessible loops); and 14-16 and 36-45 (other
solvent-accessible loops and beta turns) may be randomized to
evolve new or improved compound-binding proteins. In addition, as
discussed above, alterations in the lengths of one or more solvent
exposed loops may also be included in such directed evolution
methods.
[0093] Alternatively, changes in the .beta.-sheet sequences may
also be used to evolve new proteins. These mutations change the
scaffold and thereby indirectly alter loop structure(s). If this
approach is taken, mutations should not saturate the sequence, but
rather few mutations should be introduced. Preferably, no more than
between 3-20 changes should be introduced to the .beta.-sheet
sequences by this approach.
[0094] Sequence variation may be introduced by any technique
including, for example, mutagenesis by Taq polymerase (Tindall and
Kunkel, Biochemistry 27:6008 (1988)), fragment recombination, or a
combination thereof. Similarly, an increase of the structural
diversity of libraries, for example, by varying the length as well
as the sequence of the CDR-like loops, or by structural redesign
based on the advantageous framework mutations found in selected
pools, may be used to introduce further improvements in antibody
mimic scaffolds.
Antibody Mimic Fusions
[0095] The antibody mimics described herein may be fused to other
protein domains. For example, these mimics may be integrated with
the human immune response by fusing the constant region of an IgG
(F.sub.c) with an antibody mimic, such as an .sup.10Fn3 module,
preferably through the C-terminus of .sup.10Fn3. The F.sub.c in
such a .sup.10Fn3-F.sub.c fusion molecule activates the complement
component of the immune response and increases the therapeutic
value of the antibody mimic. Similarly, a fusion between an
antibody mimic, such as .sup.10Fn3, and a complement protein, such
as Clq, may be used to target cells, and a fusion between an
antibody mimic, such as .sup.10Fn3, and a toxin may be used to
specifically destroy cells that carry a particular antigen. In
addition, an antibody scaffold, such as .sup.10Fn3, in any form may
be fused with albumin to increase its half-life in the bloodstream
and its tissue penetration. Any of these fusions may be generated
by standard techniques, for example, by expression of the fusion
protein from a recombinant fusion gene constructed using publically
available gene sequences.
Scaffold Multimers
[0096] In addition to monomers, any of the scaffold constructs
described herein may be generated as dimers or multimers of
antibody mimics as a means to increase the valency and thus the
avidity of antigen binding. Such multimers may be generated through
covalent binding. For example, individual .sup.10Fn3 modules may be
bound by imitating the natural .sup.8Fn3-.sup.9Fn3-.sup.10Fn3
C-to-N-terminus binding or by imitating antibody dimers that are
held together through their constant regions. A .sup.10Fn3-Fc
construct may be exploited to design dimers of the general scheme
of .sup.10Fn3-Fc::Fc-.sup.10Fn3. The bonds engineered into the
Fc::Fc interface may be covalent or non-covalent. In addition,
dimerizing or multimerizing partners other than Fc can be used in
hybrids, such as .sup.10Fn3 hybrids, to create such higher order
structures.
[0097] In particular examples, covalently bonded multimers may be
generated by constructing fusion genes that encode the multimer or,
alternatively, by engineering codons for cysteine residues into
monomer sequences and allowing disulfide bond formation to occur
between the expression products. Non-covalently bonded multimers
may also be generated by a variety of techniques. These include the
introduction, into monomer sequences, of codons corresponding to
positively and/or negatively charged residues and allowing
interactions between these residues in the expression products (and
therefore between the monomers) to occur. This approach may be
simplified by taking advantage of charged residues naturally
present in a monomer subunit, for example, the negatively charged
residues of fibronectin. Another means for generating
non-covalently bonded antibody mimics is to introduce, into the
monomer gene (for example, at the amino- or carboxy-termini), the
coding sequences for proteins or protein domains known to interact.
Such proteins or protein domains include coil-coil motifs, leucine
zipper motifs, and any of the numerous protein subunits (or
fragments thereof) known to direct formation of dimers or higher
order multimers.
Fibronectin-Like Molecules
[0098] Although .sup.10Fn3 represents a preferred scaffold for the
generation of antibody mimics, other molecules may be substituted
for .sup.10Fn3 in the molecules described herein. These include,
without limitation, human fibronectin modules .sup.10Fn3-.sup.9Fn3
and .sup.10Fn3-.sup.17Fn3 as well as related Fn3 modules from
non-human animals and prokaryotes. In addition, Fn3 modules from
other proteins with sequence homology to .sup.10Fn3, such as
tenascins and undulins, may also be used. Other exemplary scaffolds
having immunoglobulin-like folds (but with sequences that are
unrelated to the V.sub.H domain) are shown in FIG. 21 and include
N-cadherin, ICAM-2, titin, GCSF receptor, cytokine receptor,
glycosidase inhibitor, E-cadherin, and antibiotic chromoprotein.
Yet further domains with related structures may be derived from
myelin membrane adhesion molecule PO, CD1, CD4, CD2, class I MHC,
T-cell antigen receptor, CD1, C2 and I-set domains of VCAM-1,1-set
immunoglobulin domain of myosin-binding protein C, 1-set
immunoglobulin domain of myosin-binding protein H, 1-set
immunoglobulin domain of telokin, telikin, NCAM, twitchin,
neuroglian, growth hormone receptor, erythropoietin receptor,
prolactin receptor, GC-SF receptor, interferon-gamma receptor,
.beta.-galactosidase/glucuronidase, .beta.-glucuronidase, and
transglutaminase. Alternatively, any other protein that includes
one or more immunoglobulin-like folds may be utilized. Such
proteins may be identified, for example, using the program SCOP
(Murzin et al., J. Mol. Biol. 247:536 (1995); Lo Conte et al.,
Nucleic Acids Res. 25:257 (2000).
[0099] Generally, any molecule that exhibits a structural
relatedness to the V.sub.H domain (as identified, for example,
using the computer program above) may be utilized as an antibody
mimic. Such molecules may, like fibronectin, include three loops at
the N-terminal pole of the molecule and three loops at the
C-terminal pole, each of which may be randomized to create diverse
libraries; alternatively, larger domains may be utilized, having
larger numbers of loops, as long as a number of such surface
randomizable loops are positioned closely enough in space that they
can participate in antigen binding. FIG. 22 shows examples of
useful domains having more than three loops positioned close to
each other. These examples include T-cell antigen receptor and
superoxide dismutase, which each have four loops that can be
randomized; and an Fn3 dimer, tissue factor domains, and cytokine
receptor domains, each of which have three sets of two similar
domains where three randomizable loops are part of the two domains
(bringing the total number of loops to six).
[0100] In yet another alternative, any protein having variable
loops positioned close enough in space may be utilized for
candidate binding protein production. For example, large proteins
having spatially related, solvent accessible loops may be used,
even if unrelated structurally to an immunoglobulin-like fold.
Exemplary proteins include, without limitation, cytochrome F, green
fluorescent protein, GroEL, and thaumatin (FIG. 23). The loops
displayed by these proteins may be randomized and superior binders
selected from a randomized library as described herein. Because of
their size, molecules may be obtained that exhibit an antigen
binding surface considerably larger than that found in an
antibody-antigen interaction. Other useful scaffolds of this type
may also be identified using the program SCOP (Murzin et al., J.
Mol. Biol. 247:536 (1995)) to browse among candidate proteins
having numerous loops, particularly loops positioned among parallel
beta sheets or a number of alpha-helices.
[0101] Modules from different organisms and parent proteins may be
most appropriate for different applications. For example, in
designing an antibody mimic, it may be most desirable to generate
that protein from a fibronectin or fibronectin-like molecule native
to the organism for which a therapeutic is intended. In contrast,
the organism of origin is less important or even irrelevant for
antibody mimics that are to be used for in vitro applications, such
as diagnostics, or as research reagents.
[0102] For any of these molecules, libraries may be generated and
used to select binding proteins by any of the methods described
herein.
Directed Evolution of Scaffold-Based Binding Proteins
[0103] The antibody mimics described herein may be used in any
technique for evolving new or improved binding proteins. In one
particular example, the target of binding is immobilized on a solid
support, such as a column resin or microtiter plate well, and the
target contacted with a library of candidate scaffold-based binding
proteins. Such a library may consist of antibody mimic clones, such
as .sup.10Fn3 clones constructed from the wild type .sup.10Fn3
scaffold through randomization of the sequence and/or the length of
the .sup.10Fn3 CDR-like loops. If desired, this library may be an
RNA-protein fusion library generated, for example, by the
techniques described in Szostak et al., U.S. Ser. No. 09/007,005
and 09/247,190; Szostak et al., WO98/31700; and Roberts &
Szostak, Proc. Natl. Acad. Sci. USA (1997) vol. 94, p. 12297-12302.
Alternatively, it may be a DNA-protein library (for example, as
described in Lohse, DNA-Protein Fusions and Uses Thereof, U.S. Ser.
No. 60/110,549, U.S. Ser. No. 09/459,190, and WO 00/32823). The
fusion library is incubated with the immobilized target, the
support is washed to remove non-specific binders, and the tightest
binders are eluted under very stringent conditions and subjected to
PCR to recover the sequence information or to create a new library
of binders which may be used to repeat the selection process, with
or without further mutagenesis of the sequence. A number of rounds
of selection may be performed until binders of sufficient affinity
for the antigen are obtained.
[0104] In one particular example, the .sup.10Fn3 scaffold may be
used as the selection target. For example, if a protein is required
that binds a specific peptide sequence presented in a ten residue
loop, a single .sup.10Fn3 clone is constructed in which one of its
loops has been set to the length of ten and to the desired
sequence. The new clone is expressed in vivo and purified, and then
immobilized on a solid support. An RNA-protein fusion library based
on an appropriate scaffold is then allowed to interact with the
support, which is then washed, and desired molecules eluted and
re-selected as described above.
[0105] Similarly, the scaffolds described herein, for example, the
.sup.10Fn3 scaffold, may be used to find natural proteins that
interact with the peptide sequence displayed by the scaffold, for
example, in an .sup.10Fn3 loop. The scaffold protein, such as the
.sup.10Fn3 protein, is immobilized as described above, and an
RNA-protein fusion library is screened for binders to the displayed
loop. The binders are enriched through multiple rounds of selection
and identified by DNA sequencing.
[0106] In addition, in the above approaches, although RNA-protein
libraries represent exemplary libraries for directed evolution, any
type of scaffold-based library may be used in the selection methods
of the invention.
Use
[0107] The antibody mimics described herein may be evolved to bind
any antigen of interest. These proteins have thermodynamic
properties superior to those of natural antibodies and can be
evolved rapidly in vitro. Accordingly, these antibody mimics may be
employed in place of antibodies in all areas in which antibodies
are used, including in the research, therapeutic, and diagnostic
fields. In addition, because these scaffolds possess solubility and
stability properties superior to antibodies, the antibody mimics
described herein may also be used under conditions which would
destroy or inactivate antibody molecules. Finally, because the
scaffolds of the present invention may be evolved to bind virtually
any compound, these molecules provide completely novel binding
proteins which also find use in the research, diagnostic, and
therapeutic areas.
Experimental Results
[0108] Exemplary scaffold molecules described above were generated
and tested, for example, in selection protocols, as follows.
Library Construction
[0109] A complex library was constructed from three fragments, each
of which contained one randomized area corresponding to a CDR-like
loop. The randomized residues are indicated in FIG. 18 as
underlined sequences, specifically, residues 23-29 of the
.sup.10Fn3 BC loop (corresponding to CDR-H1 of the llama V.sub.H);
residues 52-55 of the .sup.10Fn3 DE loop (corresponding to CDR-H2
of the llama V.sub.H); and residues 78-87 of the .sup.10Fn3 FG loop
(corresponding to CDR-H3 of the llama V.sub.H). The fragments were
named BC, DE, and FG based on the names of the CDR-H-like loops
contained within them; in addition to .sup.10Fn3 and a randomized
sequence, each of the fragments contained stretches encoding an
N-terminal His.sub.6 domain or a C-terminal FLAG peptide tag. At
each junction between two fragments (i.e., between the BC and DE
fragments or between the DE and FG fragments), each DNA fragment
contained recognition sequences for the Earl Type IIS restriction
endonuclease. This restriction enzyme allowed the splicing together
of adjacent fragments while removing all foreign, non-.sup.10Fn3,
sequences. It also allowed for a recombination-like mixing of the
three .sup.10Fn3 fragments between cycles of mutagenesis and
selection.
[0110] The wild-type, human .sup.10Fn3 gene was cloned from a human
liver library (Maxim Biotech, South San Francisco, Calif.) using
the primers Hu5PCR-NdeI 5'CATATGGTITCTGATGTTCCGAGG3'; SEQ ID NO:
28) and Hu3PCR-EcoRI (5'GAATTCCTATGTTCGGTAATTAATGGAAATTG3'; SEQ ID
NO: 29). Three different libraries were constructed from the
wild-type segments obtained by the PCR of the .sup.10Fn3 clone and
from randomized segments obtained by oligonucleotide synthesis. The
BC.sub.r-DE.sub.r-FG.sub.r library was obtained by randomizing the
selected residues in BC, DE, and FG loops; the
BC.sub.r-DE.sub.wt-FG.sub.r library was obtained by randomizing the
selected residues in BC and FG loops, leaving the DE loop sequence
wild-type; and the BC.sub.wt-DE.sub.wt-FG.sub.r library was
obtained by randomizing the selected residues in the FG loop
only.
[0111] The BC.sub.r, DE.sub.r, and FG.sub.r fragments were made
synthetically. Each fragment was assembled from two overlapping
oligonucleotides, which were first annealed, then extended to form
the double-stranded DNA form of the fragment. The oligonucleotides
that were used to construct and process the three fragments are
listed below; the "Top" and "Bottom" species for each fragment are
the oligonucleotides that contained the entire .sup.10Fn3 encoding
sequence. In these oligonucleotides designations, "N" indicates A,
T, C, or G; and "S" indicates C or G. TABLE-US-00001 HfnLbcTop
(His): (SEQ ID NO: 1) 5'- GG AAT TCC TAA TAC GAC TCA CTA TAG GGA
CAA TTA CTA TTT ACA ATT ACA ATG CAT CAC CAT CAC CAT CAC GTT TCT GAT
GTT CCG AGG GAC CTG GAA GTT GTT GCT GCG ACC CCC ACC AGG-3'
HfnLbcTop (an alternative N-terminus): (SEQ ID NO: 2) 5'- GG AAT
TCC TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG GTT
TCT GAT GTT CCG AGG GAC CTG GAA GTT GTT GCT GCG ACC CCC ACC AGC-3'
HFnLBCBot-flag8: (SEQ ID NO: 3) 5'-AGC GGA TGC CTT GTC GTC GTC GTC
CTT GTA GTC GCT CTT CCC TGT TTC TCC GTA AGT GAT CCT GTA ATA TCT
(SNN).sub.7 CCA GCT GAT CAG TAG GCT GGT GGG GGT CGC AGC -3'
HFnBC3'-flag8: (SEQ ID NO: 4) 5'-AGC GGA TGC CTT GTC GTC GTC GTC
CTT GTA GTC GCT CTT CCC TGT TTC TCC GTA AGT GAT CC-3' HFnLDETop:
(SEQ ID NO: 5) 5'- GG AAT TCC TAA TAC GAC TCA CTA TAG GGA CAA TTA
CTA TTT ACA ATT ACA ATG CAT CAC CAT CAC CAT CAC CTC TTC ACA GGA GGA
AAT AGC CCT GTC C-3' HFnLDEBot-flag8: (SEQ ID NO: 6) 5'-AGC GGA TGC
CTT GTC GTC GTC GTC CTT GTA GTC GCT CTT CGT ATA ATC AAC TCC AGG TTT
AAG GCC GCT GAT GGT AGC TGT (SNN)4 AGG CAC AGT GAA CTC CTG GAC AGG
GCT ATT TCC TCC TGT -3' HFnDE3'-flag8: (SEQ ID NO: 7) 5'-AGC GGA
TGC CTT GTC GTC GTC GTC CTT GTA GTC GCT CTT CGT ATA ATC AAC TCC AGG
TTT AAG G-3' HFnLFGTop: (SEQ ID NO: 8) 5'- GG AAT TCC TAA TAC GAC
TCA CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA ATG CAT CAC CAT CAC CAT
CAC CTC TTC TAT ACC ATC ACT GTG TAT GCT GTC-3' HFnLFGBot-flag8:
(SEQ ID NO: 9) 5'-AGC GGA TGC CTT GTC GTC GTC GTC CTT GTA GTC TGT
TCG GTA ATT AAT GGA AAT TGG (SNN).sub.10 AGT GAC AGC ATA CAC AGT
GAT GGT ATA -3' HFnFG3'-flag8: (SEQ ID NO: 10) 5'-AGC GGA TGC CTT
GTC GTC GTC GTC CTT GTA GTC TGT TCG GTA ATT AAT GGA AAT TGG -3'
T7Tmv (introduces T7 promoter and TMV untranslated region needed
for in vitro translation): (SEQ ID NO: 11) 5'- GCG TAA TAC GAC TCA
CTA TAG GGA CAA TTA CTA TTT ACA ATT ACA-3' ASAflag8: (SEQ ID NO:
12) 5'-AGC GGA TGC CTT GTC GTC GTC GTC CTT GTA GTC-3' Unispl-s
(spint oligonucleotide used to ligate mRNA to the
puromycin-containing linker, described by Roberts et al, 1997,
supra): (SEQ ID NO: 13) 5'-TTTTTTTTTNAGCGGATGC-3' A18---2PEG
(DNA-puromycin linker): (SEQ ID NO: 14)
5'-(A).sub.18(PEG).sub.2CCPur
[0112] The oligonucleotide pair BC.sub.TOP and BC.sub.Bot-flag8 was
used to construct the fragment which contains the randomized BC
loop; the pair DETop and DE.sub.Bot-flag8 was used to construct the
fragment which contains the randomized DE loop; the pair BC.sub.TOP
and DE.sub.3-Flag8 was used to PCR-amplify the BC.sub.wt-DE.sub.wt
fragments; and the pair FG.sub.Top and FG.sub.Bot-Flag8 was used to
construct the fragment which contains the randomized FG loop. The
pairs of oligonucleotides (500 pmol of each) were annealed in 100
.mu.L of 10 mM Tris 7.5, 50 mM NaCl for 10 minutes at 85.degree.
C., followed by a slow (0.5-1 hour) cooling to room temperature.
The annealed fragments with single-stranded overhangs were then
extended using 100 U Klenow (New England Biolabs, Beverly, Mass.)
for each 100 .mu.L aliquot of annealed oligos, and the buffer made
of 838.5 .mu.l H.sub.2O, 9 .mu.l 1 M Tris 7.5, 5 .mu.L 1M
MgCl.sub.2, 20 .mu.l 10 mM dNTPs, and 7.5 .mu.l 1 M DTT. The
extension reactions proceeded for 1 hour at 25.degree. C.
[0113] In order to reduce the frequency of stop codons introduced
by the random sequences, the randomized residues were encoded by
(NNS).sub.n, where N stands for any nucleotide and S for an
equimolar mixture of C and G; only one of the three stop codons
(TAG) conforms to the NNS restriction. In addition to the sequence
encoding .sup.10Fn3, the gene fragments contained the 5' Tobacco
Mosaic Virus (TMV) untranslated region and the T7 promoter, as well
as the sequences encoding a 5' hexahistidine protein purification
tag and a 3'FLAG epitope purification tag. In addition, as noted
above, Ear I restriction endonuclease recognition sites were
engineered into the overlaps between adjacent fragments in order to
facilitate the assembly of the three fragments.
[0114] Next, each of the double-stranded fragments was transformed
into an RNA-protein fusion (PROfusion.TM.) using the technique
developed by Szostak et al., U.S. Ser. No. 09/007,005 and U.S. Ser.
No. 09/247,190; Szostak et al., WO98/31700; and Roberts &
Szostak, Proc. Natl. Acad. Sci. USA (1997) vol. 94, p. 12297-12302.
Briefly, the fragments were transcribed using an Ambion in vitro
transcription kit, T7-MEGAshortscrip.TM. (Ambion, Austin, Tex.),
and the resulting mRNA was gel-purified and ligated to a
5'-phosphorylated DNA-puromycin linker, preferably, 5'
dA.sub.18PEG.sub.2dCdCPur) using DNA ligase (Promega, Madison,
Wis.); the mRNA was aligned with the DNA linker using a DNA splint
oligonucleotide (5'TTTTTTTTTNAGCGGATGC 3'; SEQ ID NO: 30) as
described in Szostak (supra). The mRNA-DNA-puromycin molecule was
then translated using the Ambion rabbit reticulocyte lysate-based
translation kit in the presence of .sup.35S-methionine. The
resulting mRNA-DNA-puromycin-protein fusion was purified using
Oligo(dT) cellulose, (Type 7, Amersham Pharmacia, Piscataway, N.J.)
and a complementary DNA strand was synthesized using reverse
transcriptase (Superscript.TM.II, Gibco, Life Technologies,
Rockville, Md.) and the RT primers described above (Unisplint-S or
flagASA), following the manufacturer's instructions (preferably, a
two-minute annealing at 70.degree. C. and a 40 minute reaction at
42.degree. C.).
[0115] The RNA-protein fusion with annealing cDNA obtained for each
fragment was next purified on the resin appropriate to its peptide
purification tag, i.e., on Ni-NTA agarose (Qiagen, Valencia,
Calif.) for the HiS.sub.6-tag and M2 Anti-Flag Agarose (Sigma, St.
Louis, Mo.) for the FLAG-tag, following the procedures recommended
by the manufacturers. The fragment-encoding genetic information
recovered by KOH elution was amplified by PCR using Pharmacia
Ready-to-Go PCR Beads, 10 pmol of 5' and 3' PCR primers, and the
following PCR program (Pharmacia, Piscataway, N.J.): Step 1:
95.degree. C. for 3 minutes; Step 2: 95.degree. C. for 30 seconds,
58/62.degree. C. for 30 seconds, 72.degree. C. for 1 minute,
20/25/30 cycles, as required; Step 3: 72.degree. C. for 5 minutes;
Step 4: 4.degree. C. until end (typically, 25 cycles).
[0116] The resulting DNA was cleaved by 5-6 U Earl (New England
Biolabs) per .mu.g DNA; the reaction took place in T4 DNA Ligase
Buffer (New England Biolabs) at 37.degree. C., for 1 hour, and was
followed by an optional incubation at 70.degree. C. for 15 minutes
to inactivate Ear I. Equal amounts of the BC, DE, and FG fragments
were combined and ligated to form a full-length .sup.10Fn3 gene
with randomized loops. The ligation required 10 U of fresh Earl
(New England Biolabs) and 20 U of T4 DNA Ligase (Promega, Madison,
Wis.), and took 1 hour at 37.degree. C. Earl and ligase were then
inactivated by a 15 minute incubation at 65.degree. C.
[0117] Three different libraries, BC.sub.wt-DE.sub.wt-FG.sub.r,
BC.sub.r-DE.sub.wtFG.sub.r, and BC.sub.rDE.sub.r-FG.sub.r, were
made in the manner described above. Each contained the form of the
FG loop with 10 randomized residues. The BC and the DE loops of the
first library bore the wild type .sup.10Fn3 sequence; a BC loop
with 7 randomized residues and a wild type DE loop made up the
second library; and a BC loop with 7 randomized residues and a DE
loop with 4 randomized residues made up the third library. The
complexity of the FG loop in each of these three libraries was
10.sup.13; the further two randomized loops provided the potential
for a complexity too large to be sampled in a laboratory. The
combination of these libraries provided a master library having
10.sup.12 unique clones.
[0118] The sequences of 76 randomly picked clones from the
original, randomized, BC.sub.r-DE.sub.r-FG.sub.r library showed no
pattern in the randomized loops (data not shown); the amino acid
frequency in the library varied in proportion to the number of
codons available that encoded each residue, between 1% per position
(glutamic acid, methionine, tryptophan) and 14% per position
(proline). In contrast, the average probability for a residue in
the preserved, beta-sheet framework to have remained as wild type
was found to be 99%.
[0119] Equimolar amounts of the three libraries (2 pmoles of DNA
each) were combined into one master library in order to simplify
the selection process; target binding itself was expected to select
the most suitable library for a particular challenge. RNA-protein
fusions were obtained from the master library following the general
procedure described in Szostak et al., U.S. Ser. No. 09/007,005 and
09/247,190; Szostak et al., WO98/31700; and Roberts & Szostak,
Proc. Natl. Acad. Sci. USA (1997) vol. 94, p. 12297-12302 (FIG. 8),
except that affinity purification performed in rounds three to ten
used only M2-Sepharose (see below).
Fusion Selections
[0120] The master library in the RNA-protein fusion form was
subjected to selection for binding to TNF-.alpha. (Pepro Tech,
Rocky Hill, N.J.). Two initial protocols were employed: one in
which the target was immobilized on an agarose column and one in
which the target was immobilized on a BIACORE chip. First, an
extensive optimization of conditions to minimize background binders
to the agarose column yielded the favorable buffer conditions of 50
mM HEPES pH 7.4, 0.02% Triton, 100 .mu.g/ml sheared salmon sperm
DNA. In this buffer, the non-specific binding of the .sup.10Fn3-RNA
fusion to TNF-.alpha. Sepharose was 0.3%. The non-specific binding
background of the .sup.10Fn3-RNA/cDNA library to TNF-.alpha.
Sepharose was found to be 0.1%.
[0121] During each round of selection on TNF-.alpha. Sepharose, the
library was first preincubated for an hour with underivatized
Sepharose to remove any remaining non-specific binders; the
flow-through from this pre-clearing was incubated for another hour
with TNF-.alpha. Sepharose. The TNF-.alpha. Sepharose was washed
for 3-30 minutes.
[0122] After each selection, the cDNA component of the complex that
had been eluted from the solid support with 0.3 M NaOH or 0.1M KOH
was amplified by PCR; a DNA band of the expected size persisted
through multiple rounds of selection (FIG. 9); similar results were
observed in the two alternative selection protocols, and only the
data from the agarose column selection is shown in FIG. 9.
[0123] In this selection, in the first seven rounds, the binding of
Fn3-RNA/cDNA molecules to the target remained low; in contrast,
when free protein was translated from DNA pools at different stages
of the selection, the proportion of the column binding species
increased significantly between rounds (FIG. 10).
[0124] In later selections, the fusion pools selected in the first
eight rounds of selection (R1-8) bound to TNF-.alpha.-Sepharose at
levels close to the background (<0.25%) (FIG. 13). After nine
rounds of selection (R9), the binding of fusion to
TNF-.alpha.-Sepharose increased sharply to 0.7%, and, after ten
rounds of selection (R10), the binding increased further to 7%
(FIG. 13). These selections were carried out using TNF-.alpha.
immobilized on Epoxy-Activated Sepharose.TM. 6B (Amersham
Pharmacia) at 10 mg TNF/g Sepharose in 10 mL. Before use, the
TNF-.alpha.-derivatized Sepharose was blocked in Binding Buffer (50
mM HEPES, pH 7.4, 0.02% Triton, 0.1 mg/mL sheared salmon sperm DNA
(Ambion)), overnight, at 4.degree. C.
[0125] The .sup.10Fn3-based master library was transcribed, ligated
to the puromycin-bearing linker, translated into an mRNA-protein
library in the presence of 5-.mu.L/300 .mu.L .sup.35S-methionine,
affinity purified on Oligo(dT) Cellulose, reverse-transcribed into
a DNA/mRNA-protein library, and affinity-purified on M2-Sepharose
(for rounds 3-10), as described above. Forty pmol of
DNA/mRNA-protein fusion library molecules, the equivalent of 20
copies of 4.times.10.sup.12 different sequences, were recovered,
then subjected to the first round (R1) of the selection.
[0126] In the first step of the selection, 40 pmoles of the
DNA/mRNA-protein library was incubated for 1 hour at 4.degree. C.,
with tumbling, in 300 .mu.L of Binding Buffer with 30 .mu.L of
Epoxy-Sepharose that had been subjected to the derivatization
procedure in the absence of TNF-.alpha.. In the second round, 24
.mu.mol of the library was added, and in the remaining eight
rounds, 0.1-2 .mu.mol of the library was added. The supernatant was
recovered by microcentrifugation through a Micro Bio-Spin.RTM.
chromatography column (BIO-RAD, Hercules, Calif.), then incubated
with 30 .mu.L of TNF-.alpha.-Sepharose (6 .mu.M) in 300 .mu.L of
the Binding Buffer for 1 hour at 4.degree. C. (during Rounds 7-10,
the Binding Buffer contained an additional 1 mg/mL of BSA). The
TNF-.alpha.-Sepharose was recovered on a spin column, then washed
with 3.times.300 .mu.L of Binding Buffer, eluted with 100 .mu.L of
0.1 M KOH, and finally neutralized with 1 .mu.L of 1. M Tris 8.0, 8
.mu.L of 1 M HCl. Samples of the library, of the
TNF-.alpha.-Sepharose before and after the elution, of the washes,
and of the elutions were quantified by counting .sup.35S-methionine
in the sample in a scintillation counter. The next round of
selection began with the formation of a new DNA/mRNA-protein pool
by PCR amplification, which was transcribed, translated, and
reverse-transcribed from the PCR product.
[0127] The DNA pools obtained from the elution after nine and after
ten rounds were cloned into the TOPO.TM. TA.RTM., pCR2.1 cloning
vector (Invitrogen, Carlsbad, Calif.) and transformed into E. coli.
Between 30 and 100 clones were picked and grown into plasmid
minipreps (Qiagen). Thirty-eight clones from R9 and 29 clones from
R10 were picked at random and sequenced (DNA Sequencing Core
Facility, Massachusetts General Hospital, Dept. of Molecular
Biology, Boston, Mass.). The program ClustalW.sup.60 was used to
align the resulting protein sequences.
Amino Acid Residue Sequences of the TNF-.alpha. Binding Clones
[0128] Thirty-eight of the 61 clones derived from R9 and from R10
had unique amino acid sequences, a surprising diversity. The ten
clones that were isolated more than once, presumably because of
their superior binding to TNF-.alpha., are listed in Table 1 (full
sequences in FIG. 25).
[0129] Of the 61 clones picked randomly from the winning pool, only
one (clone T09.08, sequence not shown) had its origin in the
BC.sub.wt-DE.sub.wt-FG.sub.r library, with another six from the
BC.sub.r-DE.sub.wt-FG.sub.r library. The observation that the
remaining 54 (88% of the winners) were selected from the
BC.sub.r-DE.sub.r-FG.sub.r library points out the importance for
TNF-.alpha. cooperative binding of the target by several loops.
[0130] The most common motif found in the selected loop sequences
is PWA(Sfr), which is found in the DE loop of 33 of the 61 clones;
the more loosely defined sequence of PW(A/G) is seen in 41/61
clones. Such a strong selection for a specific DE sequence is
surprising since the analogous CDR-H2 loops of antibody V.sub.H
domains generally make only a small contribution to antigen
binding. On the other hand, the short length of the DE loop, which
means that 10.sup.7 copies of each possible tetrapeptide sequence
would be expected to be present in the library, would facilitate
the optimization of any contribution of the DE loop to the selected
properties. A survey of other Fn3 domains (Dickenson et al., J.
Mol. Biol. 236:1079-1092 (1994)) shows that proline is found at
positions equivalent to the .sup.10Fn3 residue 52 as frequently as
is the wild-type glycine; similarly, alanine, glycine, and the
wild-type lysine are all common at positions equivalent to the
.sup.10Fn3 position 54. In consequence, it appears likely that the
selected residues at positions 52 and 54 are at least consistent
with favorable biophysical properties. In contrast, no tryptophan
is found at the position equivalent to the .sup.10Fn3 residue 53,
which suggests that Tryptophan 53 may have been selected for a
reason specific to the present selection, such as due to a
contribution to TNF-.alpha. binding. This is consistent with the
absence of this motif in later selections against other antigens,
again suggesting that the PWA/G motif is more likely to contribute
to TNF-.alpha. binding directly than through stability or
solubility of the .sup.10Fn3 domain. The preference for the PWA/G
motif on loop DE suggests another possible reason for the
preference for the BC.sub.r-DE.sub.r-FG.sub.r library during the
selection: the BC.sub.r-DE.sub.r-FG.sub.r library alone contained
the randomized DE loop, and would be expected to outcompete the
other two libraries if the PWA/G sequence were important to target
binding.
[0131] The sequences selected most frequently in the BC loop is
NRSGLQS (12/61) (SEQ ID NO: 31), whereas the sequence selected most
commonly in the FG loop is AQTGHHLHDK (6/61) (SEQ ID NO: 32). An
NRSGLQS BC loop and an AQTGHHLHDK FG loop have not been found in
the same molecule, but two clones were found which contain the most
frequently isolated sequences on two of the three randomized loops.
These clones, T10.06 (BC: NRSGLQS, DE: PWA) and T09.12 (DE: PWA,
FG: AQTGHBLHDK), have two of the lowest four dissociation constants
from TNF-.alpha. of the clones examined (Table 1).
[0132] Due to the use of a Taq polymerase that contains no
proofreading activity, every round of PCR introduced additional
random mutations into both the CDR-like loops and the beta-sheet
scaffold of the .sup.10Fn3 sequence, at the estimated rate of 0.01%
per base pair, i.e., 3% per .sup.10Fn3 gene per round of PCR and
approximately 75% per round of selection. Consequently, it is
likely that the residues preserved as wild-type and those preserved
in a non-wild-type stable sequence indicate that such sequences
were selected due to their superior properties. In the mutated
loops, it is impossible to distinguish between the mutations
introduced by oligonucleotide synthesis or by PCR mutagenesis, but
in the beta-strand scaffold, most of the mutations selected
originate from Taq errors. The selected clones showed several
conserved changes in the scaffold of the protein, which had not
been randomized intentionally. FIG. 18 indicates the residues in
the .sup.10Fn3 beta sheet that had not been randomized, but
nevertheless mutated during selection. This mutagenesis occurred at
the frequency of 26-28 of the 61 clones; these mutations are marked
with arrows under the wild-type .sup.10Fn3 sequence and with the
letter that identifies the selected residue. In particular, 28 of
the 61 clones mutated from Leucine 18 to Arginine or to Glutamine,
and 26 clones mutated from Threonine 56 to Isoleucine. FIG. 19
shows the location of these scaffold mutations. Whereas position 56
is at the stem loop DE and thus would be expected to affect the
conformation and the target-binding properties of this loop, the
distance of position 18 from the presumed TNF-.alpha.-binding loops
suggests that the selective advantage of this mutation may arise
from an indirect effect on the conformation of loop BC or from an
effect on the stability of the protein (FIG. 19). This is supported
by an experiment in which clone T10.06, which contains the
frequently seen L18R and T56I changes from the wild-type, was
mutagenized to reverse position 18 back to the wild-type leucine.
This change caused an increase of the K.sub.d of the variant by
approximately 10-fold. The weaker binding of the T10.06(L18)
protein to TNF-.alpha. suggests that the residue at position 18 has
an effect on the binding of the target by the CDR-like loops,
possibly by a minor structural change that is transmitted through
the beta-strand to loop BC.
Affinity and Specificity of the Selected TNF-.alpha. Binding
Pools
[0133] The apparent average K.sub.d values of free protein pools
for TNF-.alpha. after nine and after ten rounds of selection were
found to be indistinguishable (4 and 6 nM, respectively; Table 1);
this similarity in affinity is consistent with the relatively low
(10 fold) level of enrichment observed in the last round of
selection and with the similarity in the sequence composition of
the two pools. The apparent average Kd values of free protein pool
after four further rounds of selection was 3 nM, also
indistinguishable from those of R9 and R10 pools
[0134] In order to assess the specificity of the binding of the
pool selected after ten rounds of selection, we compared the
binding of two different free protein pools to three cytokines
immobilized on Sepharose to TNF-.alpha., the target of the
selection, and to IL-1.alpha. and IL-13, which were irrelevant to
the selection. The first pool had been transcribed and translated
from the initial, randomized DNA library before the selection (R0),
and the second pool, from the library after ten rounds of selection
(R10).
[0135] To carry out these experiments, the PCR product of the
elution after the tenth round of selection was transcribed and
translated in vitro, in the presence of .sup.35S-methionine but
without forming the mRNA-protein fusion. The resulting fraction of
the free protein bound to TNF-.alpha.-Sepharose, to
IL-1.alpha.-Sepharose, to IL-13-Sepharose at approximately 10
.mu.M, 30 .mu.M, and 50 .mu.M, respectively, and to underivatized
Sepharose was compared (FIG. 20), using the procedure described
above for DNA/mRNA-protein fusion binding to TNF-.alpha.-Sepharose.
The amount of the selected pool bound to each of the targets was
measured by scintillation counting of the washed beads.
[0136] FIG. 20 shows that, whereas the binding of R0 to
TNF-.alpha., IL-1.alpha., and IL-13 was similar (2%, 4%, and 3%,
respectively), the ten rounds of selection resulted in 32% binding
to the targeted TNF-.alpha., in 3% binding to IL-1.alpha., and in
1% binding to IL-13. The absolute and the relative increase of
protein binding to TNF-.alpha. demonstrates the ability of the
.sup.10Fn3 scaffold and of the DNA/mRNA-protein fusion-based
selection system to select target-specific binders.
[0137] To examine the specificity of binding further, clone T09.12
was immobilized in a microarray format (as generally described
below) and was tested for binding to soluble TNF-.alpha.. Specific
binding of TNF-.alpha. to this clone was detected using
fluorescence detection (FIG. 24A) and mass spectroscopy (FIG. 24B).
For the mass spectroscopy results, binding assays were carried out
in the presence of fetal bovine serum, an exemplary complex
biological fluid containing a variety of potential interfering
proteins. For fluorescence detection (FIG. 24A), a mixture of
RNA-.sup.10Fn3 fusion of wild-type .sup.10Fn3 and of the T09.12
variant (Table 1) was hybridized onto a DNA microarray on which
oligonucleotides complementary to the RNA portion of the fusion
molecules had been immobilized at 600 micron pitch, with 24
replicate features. After removal of unhybridized fusion by
washing, the surface was exposed to biotin-TNF-.alpha. (2.6 .mu.g/L
in TBS, 0.02% Tween-20, 0.2% BSA), washed, and air-dried. The
captured biotin-TNF-.alpha.was detected by Cy3-labeled anti-biotin
monoclonal antibody (Sigma) using a ScanArray 5000 system (GSI
Lumonics). For mass spectroscopy detection, RNA-.sup.10Fn3 fusion
of the T09.12 variant (FIG. 24B) and wild-type .sup.10Fn3 (FIG.
24C) was treated with RNase A to generate a fusion between the
protein and the DNA linker. The resulting DNA-linked protein was
hybridized to a glass coverslip arrayed with an immobilized
oligonucleotide complementary to the DNA linker (FIGS. 24B and 24C;
no fusion was applied in FIG. 24D). After washing, the above
surfaces were exposed to TNF-.alpha. (1.5 mg/mL in 90% v/v PBS/10%
fetal bovine serum). The dried chip was spotted with MALDI matrix
and analyzed with a Voyager DE MALDI-TOF mass spectrometer
(PerSeptive Biosystems). A signal at 17.4 kD, which corresponded to
the expected molecular mass of monomeric TNF-.alpha., was detected
on the 200 .mu.m features that contained T09.12 protein (FIG. 24A),
but not on the features that contained wild-type .sup.10Fn3 (FIG.
24B) nor on the features that did not contain DNA-protein fusion
(FIG. 24C).
K.sub.d of the Selected TNF-.alpha. Binding Clones
[0138] Dissociation constants were determined for all the clones
that were represented more than once in the two pools generated
after nine and after ten rounds of selection, as well as for the
only clone that originated from the BC.sub.wt-DE.sub.tw-FG.sub.r
library (clone T09.08).
[0139] To determine these binding constants, biotinylated
TNF-.alpha. was prepared using the NHS-LC-LC-Biotin reagent
supplied by Pierce (Rockford, Ill.). MALDI-TOF mass spectrometry
was used to estimate that more than 80% of the monomeric
TNF-.alpha., and hence more than 99% of the trimer, was
biotinylated.
[0140] For the R9 and R10 pools (and the R14 and M12 pools
discussed below), as well as for the characterized clones derived
from these two pools, eleven samples of 0.25 nM, in
vitro-translated, .sup.35S-methionine-labeled free protein were
incubated with the biotinylated TNF-.alpha. at a concentration
between 17 pM and 23 nM, in 200 .mu.L 10 mM HEPES, pH 7.4, 150 mM
NaCl, 1% BSA, 0.02% Triton, for one hour at room temperature.
Subsequently, each sample was loaded on a pre-soaked, SAM.sup.2R
Biotin Capture Membrane (Promega, Madison, Wis.) using a 96 well,
Easy-Titer.TM. ELIFA system (Pierce). Under vacuum, each spot was
washed with 200 .mu.L of HBS pH 7.4, 1% BSA, 0.05% Triton; next the
entire membrane was rinsed in the buffer and air-dried. The
membrane was exposed with a Storage Phosphor Screen (Molecular
Dynamics, Sunnyvale, Calif.) overnight, and the intensities of the
resulting individual spots were quantified using a STORM 860
phosphoimager with the ImageQuaNT densitometry program (Molecular
Dynamics). The K.sub.d of the binding was determined by fitting the
equilibrium equation to the resulting binding curve (KaleidaGraph,
Synergy Software); the error of the experiment was estimated from
24 independent experiments.
[0141] In these studies, the K.sub.d values were found to be in the
narrow range of 1-24 nM (Table 1). The T09.12 and T10.06 clones,
which contained the most commonly isolated sequences in two loops
each, have the low K.sub.d of 4 and 2 nM, respectively; on the
other hand, a number of clones with less frequently seen loops,
such as clones T09.07 and T10.15, showed similarly tight
binding.
[0142] A sample comparison of TNF-.alpha. binding between free
protein and the cDNA/mRNA-protein complex derived from the same
sequence showed that the two dissociation constants were within
experimental error of each other, a property of the system that
makes it possible to use the cDNA/mRNA-protein complex to select
for target-binding properties of the protein itself.
High-Stringency Selection of TNF-.alpha. Binding Clones
[0143] Despite the duplicate clones isolated, the
TNF-.alpha.-binding pools after nine and after ten rounds of
selection contained numerous different clones, i.e., 38 different
sequences in 61 clones sampled. Therefore, further selection, with
more stringent binding requirements, was undertaken to recover a
subset of these clones with superior TNF-.alpha. binding
properties. Consequently, four further rounds of selections
(R11-R14) were conducted in solution, where the concentration of
the target was controlled more easily. The concentration of
TNF-.alpha. was limited to 0.5 nM and the concentration of
DNA/mRNA-.sup.10Fn3 pool to 0.1 nM; in addition, the length and the
temperature of the washes of the .sup.10Fn3/TNF-.alpha. complex
bound to streptavidin-coated paramagnetic beads were increased.
[0144] Specifically, these selections were carried out as follows.
For rounds 11-13, 0.1 nM DNA/mRNA-.sup.10Fn3 fusion library, which
had been made as described above, was pre-cleared by tumbling for 1
hour at 4.degree. C. with 100 .mu.L of Dynabeads.RTM. M-280
(streptavidin-coated paramagnetic beads; Dynal, Lake Success, N.Y.)
that had been pre-blocked in Binding Buffer. The resulting
pre-cleared fusion mixture was combined with 0.5 nM biotinylated
TNF-.alpha. in 300 .mu.L of the above Binding Buffer, and the
complex incubated at 4.degree. C. for 1 hour. Next, 100 .mu.l of
resuspended Dynabeads.RTM. M-280 Streptavidin at 1.3 g/cm.sup.3,
which had been blocked by overnight incubation in Binding Buffer,
were added to the mixture and incubated at 4.degree. C., with
tumbling, for 45 additional minutes. The paramagnetic beads were
separated from the supernatant on a Dynal MPC-S rack, the
supernatant was removed, and the beads were washed with the Binding
Buffer for 1, 15, and 30 minutes in the case of R11 and R12, or for
1 minute, followed by nine ten-minute washes in the case of
R13-R14. DNA was eluted from the washed
DNA/mRNA-.sup.10Fn3:TNF-.alpha.-biotin:streptavidin-bead complexes
with two washes of 100 .mu.L 0.1 M KOH, and treated as described
above for the column-based selection to produce the next generation
DNA/mRNA-.sup.10Fn3 fusion library. Round 14 differed from R11-R13
in that the selection was performed at 30.degree. C. and in the
presence of an additional 150 mM NaCl. Except for the elevated
temperature, the sequence of washes was the same for R14 as for
R13.
[0145] Twenty-two clones derived from the DNA eluted after four
further rounds of selection (R14) were picked at random and found
to represent 15 different loop sequences (Table 2; full sequences
in FIG. 25). The clone T10.06, isolated previously from R10 as
described above, was picked eight separate times, whereas the
remaining sequences, including T09.31, which had been isolated from
the R9 pool, were found in one isolate each. Similar to the
isolates from rounds nine and ten, the R14 clones examined showed a
preference (18 of 22 clones) for the PWA/G sequence in the DE loop,
and four new, non-wild-type DE sequences were revealed.
[0146] Whereas the apparent average K.sub.d values of the R14 free
protein pool, 3 nM, is similar to those measured for the pools
after nine and ten rounds (4 and 6 nM, respectively), several
K.sub.d values of the clones isolated from the R14 pool were an
order of magnitude lower than the lowest values observed in the R9
and R10 pools (Table 2). The clones that bound TNF-.alpha. most
tightly, T14.07 and T14.25, had a K.sub.d of 90 .mu.mol. Thus, the
conditions used in the last four rounds of selections were
stringent enough to favor .sup.10Fn3 molecules with subnanomolar
K.sub.d, but not so stringent as to eliminate such molecules.
Mutagenic Affinity Maturation
[0147] As discussed above, the selections described herein may also
be combined with mutagenesis after all or a subset of the selection
steps to further increase library diversity. In one parallel
selection strategy, error-prone PCR was incorporated into the
amplification of DNA between rounds (Cadwell and Joyce, PCR Methods
Appl 2:28 (1992)). This technique was carried out beginning with
the diverse DNA pool eluted after R8 above. This pool was amplified
using error-prone PCR, with the pool divided into seven equal parts
and mutagenized at the target frequency of 0.8%, 1.6%, 2.4%, 3.2%,
4.0%, 4.8%, and 5.6%. The seven PCR reactions were combined, and
cDNA/RNA-protein fusion was made from the mixture and subjected to
a round of selection in solution. Before the second mutagenic
round, M10, error-prone PCR was performed in three separate
reactions, at 0.8%, 1.6%, and 2.4%. The two remaining rounds, M11
and M12, were performed using standard Taq PCR. Except for
mutagenesis, the selection conditions for M9-M12 were the same as
for R11-R14. The twenty M12 clones tested showed tighter binding to
TNF-.alpha. than the clones selected using the two earlier
selection protocols (Table 3; full sequences in FIG. 25); the
tightest binding of TNF-.alpha. was seen in M12.04, and had the
observed K.sub.d of 20 .mu.M. These results demonstrated that
low-level, random mutagenesis late in a selection can improve both
the binding affinity of selected antibody mimics (20 .mu.M vs. 90
.mu.M) and the speed with which they can be selected (12 rounds vs.
14 rounds). In, addition, the frequency of tight binders in this
mutagenesis approach was observed to be about 5%, whereas the
frequency is approximately 3% in other selections.
Superiority of Fn Binders
[0148] The selection of .sup.10Fn3 variants capable of binding to
TNF-.alpha., performed using covalent mRNA-protein fusion as the
unit of selection, was won by molecules with dissociation constants
as low as 20 .mu.M. These K.sub.d values compared favorably against
the standards of selection of others that used other antibody mimic
scaffolds and selection methods. Consequently, the .sup.10Fn3-based
scaffold and covalent mRNA-protein fusion-based in vitro selection
method may be utilized for the development of antibody mimics
against a broad range of antigens. In addition, the subnanomolar,
TNF-.alpha.-binding .sup.10Fn3 variants described herein represent
potential therapeutic, research, and diagnostic agents. Moreover,
since this in vitro selection method can be automated, such a
combination of scaffold and selection methods have applications on
the genomic scale.
[0149] One of the factors that contributed to the success of the
present selection was the randomization of all three CDR-like loops
of .sup.10Fn3; similar libraries which contained only one or two
randomized loops were less likely to include tight binders than the
library with three randomized, CDR-like loops.
[0150] In the selection reported above, the randomized loops
remained the length of the corresponding, wild-type .sup.10Fn3
loops. To generate further library diversity, the length of the
loops as well as their sequences may be varied, to incorporate
favorable mutations in the .sup.10Fn3 beta-sheet into the wild-type
scaffold used for library construction, and to create libraries
with randomized beta-sheet scaffolds which will allow selection of
structures even more successful at mimicking antibodies.
[0151] Selections similar to those described herein may be carried
out with any other binding species target (for example, IL-1 or
IL-13).
Animal Studies
[0152] Wild-type .sup.10Fn3 contains an integrin-binding
tripepetide motif, Arginine 78-Glycine 79-Aspartate 80 (the "RGD
motif") at the tip of the FG loop. In order to avoid integrin
binding and a potential inflammatory response based on this
tripeptide in vivo, a mutant form of .sup.10Fn3 was generated that
contained an inert sequence, Serine 78-Glycine 79-Glutamate 80 (the
"SGE mutant"), a sequence which is found in the closely related,
wild-type .sup.11Fn3 domain. This SGE mutant was expressed as an
N-terminally His.sub.6-tagged, free protein in E. coli, and
purified to homogeneity on a metal chelate column followed by a
size exclusion column.
[0153] In particular, the DNA sequence encoding
His.sub.6-.sup.10Fn3(SGE) was cloned into the pET9a expression
vector and transformed into BL21 DE3 pLysS cells. The culture was
then grown in LB broth containing 50 .mu.g/mL kanamycin at
37.degree. C., with shaking, to A.sub.560=1.0, and was then induced
with 0.4 mM IPTG. The induced culture was further incubated, under
the same conditions, overnight (14-18 hours); the bacteria were
recovered by standard, low speed centrifugation. The cell pellet
was resuspended in 1/50 of the original culture volume of lysis
buffer (50 mM Tris 8.0, 0.5 M NaCl, 5% glycerol, 0.05% Triton
X-100, and 1 mM PMSF), and the cells were lysed by passing the
resulting paste through a Microfluidics Corporation Microfluidizer
M110-EH, three times. The lysate was clarified by centrifugation,
and the supernatant was filtered through a 0.45 .mu.m filter
followed by filtration through a 0.2 .mu.m filter. 100 mL of the
clarified lysate was loaded onto a 5 mL Talon cobalt column
(Clontech, Palo Alto, Calif.), washed by 70 mL of lysis buffer, and
eluted with a linear gradient of 0-30 mM imidazole in lysis buffer.
The flow rate through the column through all the steps was 1
mL/min. The eluted protein was concentrated 10-fold by dialysis (MW
cutoff=3,500) against 15,000-20,000 PEG. The resulting sample was
dialysed into buffer 1 (lysis buffer without the glycerol), then
loaded, 5 mL at a time, onto a 16.times.60 mm Sephacryl 100 size
exclusion column equilibrated in buffer 1. The column was run at
0.8 mL/min, in buffer 1; all fractions that contained a protein of
the expected MW were pooled, concentrated 10.times. as described
above, then dialyzed into PBS. Endotoxin screens and animal studies
were performed on the resulting sample (Toxikon; MA).
[0154] The endotoxin levels in the samples examined to date have
been below the detection level of the assay. In a preliminary
animal toxicology study, this protein was injected into two mice at
the estimated 100.times. therapeutic dose of 2.6 mg/mouse. The
animals survived the two weeks of the study with no apparent ill
effects. These safety results support the use of .sup.10Fn3
incorporated into an IV drug.
Alternative Constructs for In Vivo Use
[0155] To extend the half life of the 8 kD .sup.10Fn3 domain, a
larger molecule has also been constructed that mimics natural
antibodies. This .sup.10Fn3-F.sub.c molecule contains the
--CH.sub.1--CH.sub.2--CH.sub.3 (FIG. 11) or --CH.sub.2--CH.sub.3
domains of the IgG constant region of the host; in these
constructs, the .sup.10Fn3 domain is grafted onto the N-terminus in
place of the IgG V.sub.H domain (FIGS. 11 and 12). Such
antibody-like constructs are to improve the pharmacokinetics of the
protein as well as its ability to harness the natural immune
response.
[0156] In order to construct the murine form of the
.sup.10Fn3-CH.sub.1--CH.sub.2--CH.sub.3 clone, the
--CH.sub.1--CH.sub.2--CH.sub.3 region was first amplified from a
mouse liver spleen cDNA library (Clontech), then ligated into the
pET25b vector. The primers used in the cloning were 5' Fc Nest and
3' 5 Fc Nest, and the primers used to graft the appropriate
restriction sites onto the ends of the recovered insert were 5'Fc
HIII and 3'Fc Nhe: TABLE-US-00002 5' Fc Nest (SEQ ID NO: 15) 5'GCG
GCA GGG TTT GCT TAC TGG GGC CAA GGG 3'; 3' Fc Nest (SEQ ID NO: 16)
5'GGG AGG GGT GGA GGT AGG TCA CAG TCC 3'; 3' Fc Nhe (SEQ ID NO: 17)
5' TTT GCT AGC TTT ACC AGG AGA GTG GGA GGC 3'; and 5' Fc HIII (SEQ
ID NO: 18) 5' AAA AAG CTT GCC AAA ACG ACA CCC CCA TCT GTC 3'.
[0157] Further PCR was used to remove the CH.sub.1 region from this
clone and to create the Fc part of the shorter,
.sup.10Fn3-CH.sub.2--CH.sub.3 clone. The sequence encoding
.sup.10Fn3 was spliced onto the 5' end of each clone; either the
wild type .sup.10Fn3 cloned from the same mouse spleen cDNA library
or a modified .sup.10Fn3 obtained by mutagenesis or randomization
of the molecules can be used. The oligonucleotides used in the
cloning of murine wild-type .sup.10Fn3 were: TABLE-US-00003 Mo
5PCR-NdeI: (SEQ ID NO: 19) 5' CATATGGTTTCTGATATTCCGAGAGATCTGGAG 3';
Mo5PCR-His-NdeI (for an alternative N-terminus with the His.sub.6
purification tag): (SEQ ID NO: 20) 5' CAT ATG CAT CAC CAT CAC CAT
CAC GTT TCT GAT ATT CCG AGA G 3'; and Mo3PCR-EcoRI: (SEQ ID NO: 21)
5' GAATTCCTATGTTTTATAATTGATGGAAAC3'.
[0158] The human equivalents of the clones are constructed using
the same strategy with human oligonucleotide sequences.
Antibody Mimics in Protein Chip Applications
[0159] Any of the antibody mimics described herein may be
immobilized on a solid support, such as a microchip. The
suitability of the present scaffolds, for example, the .sup.10Fn3
scaffold, for protein chip applications is the consequence of (1)
their ability to support many binding functions which can be
selected rapidly on the bench or in an automated setup, and (2)
their superior biophysical properties.
[0160] The versatile binding properties of .sup.10Fn3 are a
function of the loops displayed by the Fn3 immunoglobulin-like,
beta sandwich fold. As discussed above, these loops are similar to
the complementarity determining regions of antibody variable
domains and can cooperate in a way similar to those antibody loops
in order to bind antigens. In our system, .sup.10Fn3 loops BC (for
example, residues 21-30), DE (for example, residues 51-56), and FG
(for example, residues 76-87) are randomized either in sequence, in
length, or in both sequence and length in order to generate diverse
libraries of mRNA-.sup.10Fn3 fusions. The binders in such libraries
are then enriched based on their affinity for an immobilized or
tagged target, until a small population of high affinity binders
are generated. Also, error-prone PCR and recombination can be
employed to facilitate affinity maturation of selected binders. Due
to the rapid and efficient selection and affinity maturation
protocols, binders to a large number of targets can be selected in
a short time.
[0161] As a scaffold for binders to be immobilized on protein
chips, the .sup.10Fn3 domain has the advantage over antibody
fragments and single-chain antibodies of being smaller and easier
to handle. For example, unlike single-chain scaffolds or isolated
variable domains of antibodies, which vary widely in their
stability and solubility, and which require an oxidizing
environment to preserve their structurally essential disulfide
bonds, .sup.10Fn3 is extremely stable, with a melting temperature
of 110.degree. C., and solubility at a concentration >16 mg/mL.
The .sup.10Fn3 scaffold also contains no disulfides or free
cysteines; consequently, it is insensitive to the redox potential
of its environment. A further advantage of .sup.10Fn3 is that its
antigen-binding loops and N-terminus are on the edge of the
beta-sandwich opposite to the C-terminus; thus the attachment of a
.sup.10Fn3 scaffold to a chip by its C-terminus aligns the
antigen-binding loops, allowing for their greatest accessibility to
the solution being assayed. Since .sup.10Fn3 is a single domain of
only 94 amino acid residues, it is also possible to immobilize it
onto a chip surface at a higher density than is used for
single-chain antibodies, with their approximately 250 residues. In
addition, the hydrophilicity of the .sup.10Fn3 scaffold, which is
reflected in the high solubility of this domain, minimizes unwanted
binding of .sup.10Fn3 to a chip surface.
[0162] The stability of the .sup.10Fn3 scaffold as well as its
suitability for library formation and selection of binders are
likely to be shared by the large, Fn3-like class of protein domains
with an immunoglobulin-like fold, such as the domains of tenascin,
N-cadherin, E-cadherin, ICAM, titin, GCSF-R, cytokine receptor,
glycosidase inhibitor, and antibiotic chromoprotein. The key
features shared by all such domains are a stable framework provided
by two beta-sheets, which are packed against each other and which
are connected by at least three solvent-accessible loops per edge
of the sheet; such loops can be randomized to generate a library of
potential binders without disrupting the structure of the framework
(as described above). In addition, as with .sup.10Fn3, any of these
loops (or similar loops from other proteins) may be immobilized
alone or in combination with other loops onto a solid support
surface.
Immobilization of Fn3-Based Antibody Mimics
[0163] To immobilize antibody mimics, such as Fn3-based antibody
mimics, to a chip surface, a number of exemplary techniques may be
utilized. For example, such antibody mimics may be immobilized as
RNA-protein fusions by Watson-Crick hybridization of the RNA moiety
of the fusion to a base complementary DNA immobilized on the chip
surface (as described, for example, in Addressable Protein Arrays,
U.S. Ser. No. 60/080,686; U.S. Ser. No. 09/282,734; and WO
99/51773; and Methods for Encoding and Sorting In Vitro Translated
Proteins, U.S. Ser. No. 60/151,261 and U.S. Ser. No. 09/648,040).
Alternatively, antibody mimics can be immobilized as free proteins
directly on a chip surface. Manual as well as robotic devices may
be used for deposition of the antibody mimics on the chip surface.
Spotting robots can be used for deposition of antibody mimics with
high density in an array format (for example, by the method of
Lueking et al., Anal Biochem. 1999 May 15; 270(1):103-11).
Different methods may also be utilized for anchoring the antibody
mimic on the chip surface. A number of standard immobilization
procedures may be used including those described in Methods in
Enzymology (K. Mosbach and B. Danielsson, eds.), vols. 135 and 136,
Academic Press, Orlando, Fla., 1987; Nilsson et al., Protein Expr.
Purif. 1997 October; 11(1):1-16; and references therein. Oriented
immobilization of antibody mimics can help to increase the binding
capacity of chip-bound antibody mimics. Exemplary approaches for
achieving oriented coupling are described in Lu et al., The Analyst
(1996), vol. 121, p. 29R-32R; and Turkova, J Chromatogr B Biomed
Sci App. 1999 Feb. 5; 722(1-2): 11-31. In addition, any of the
methods described herein for anchoring antibody mimics to chip
surfaces can also be applied to the immobilization of antibody
miumics on beadsi or other supports.
Target Protein Capture and Detection
[0164] Selected populations of scaffold-binders may be used for
detection and/or quantitation of analyte targets, for example, in
samples such as biological samples. To carry out this type of
diagnostic assay, selected scaffold-binders to targets of interest
are immobilized on an appropriate support to form multi-featured
protein chips. Next, a sample is applied to the chip, and the
components of the sample that associate with the binders are
identified based on the target-specificity of the immobilized
binders. Using this technique, one or more components may be
simultaneously identified or quantitated in a sample (for example,
as a means to carry out sample profiling).
[0165] Methods for target detection allow measuring the levels of
bound protein targets and include, without limitation, radiography,
fluorescence scanning, mass spectroscopy (MS), and surface plasmon
resonance (SPR). Autoradiography using a phosphorimager system
(Molecular Dynamics, Sunnyvale, Calif.) can be used for detection
and quantification of target protein which has been radioactively
labeled, e.g., using .sup.35S methionine. Fluorescence scanning
using a laser scanner (see below) may be used for detection and
quantification of fluorescently labeled targets. Alternatively,
fluorescence scanning may be used for the detection of
fluorescently labeled ligands which themselves bind to the target
protein (e.g., fluorescently labeled target-specific antibodies or
fluorescently labeled streptavidin binding to target-biotin, as
described below).
[0166] Mass spectroscopy can be used to detect and identify bound
targets based on their molecular mass. Desorption of bound target
protein can be achieved with laser assistance directly from the
chip surface as described below. Mass detection also allows
determinations, based on molecular mass, of target modifications
including post-translational modifications like phosophorylation or
glycosylation. Surface plasmon resonance can be used for
quantification of bound protein targets where the
scaffold-binder(s) are immobilized on a suitable gold-surface (for
example, as obtained from Biacore, Sweden).
[0167] Described below are exemplary schemes for selecting binders
(in this case, Fn-binders specific for the protein, TNF-.alpha.)
and the use of those selected populations for detection on chips.
This example is provided for the purpose of illustrating the
invention, and should not be construed as limiting.
[0168] Selection of TNF-.alpha. Binders Based on .sup.10Fn3
Scaffold
[0169] In one exemplary use for scaffold selection on chips, an
.sup.10Fn3-based selection was performed against TNF-.alpha., using
a library of human .sup.10Fn3 variants with randomized loops BC,
DE, and FG. The library was constructed from three DNA fragments,
each of which contained nucleotide sequences that encoded
approximately one third of human .sup.10Fn3, including one of the
randomized loops. The DNA sequences that encoded the loop residues
listed above were rebuilt by oligonucleotide synthesis, so that the
codons for the residues of interest were replaced by (NNS).sub.n,
where N represents any of the four deoxyribonucleotides (A, C, G,
or T), and S represents either C or G. The C-terminus of each
fragment contained the sequence for the FLAG purification tag.
[0170] Once extended by Klenow, each DNA fragment was transcribed,
ligated to a puromycin-containing DNA linker, and translated in
vitro, as described by Szostak et al. (Roberts and Szostak, Proc.
Natl. Acad. Sci. USA 94:12297, 1997; Szostak et al., U.S. Ser. No.
09/007,005 and U.S. Ser. No. 09/247,190; Szostak et al.,
WO98/31700), to generate an mRNA-peptide fusion, which was then
reverse-transcribed into a DNA-mRNA-peptide fusion. The binding of
the FLAG-tagged peptide to M2 agarose separated full-length fusion
molecules from those containing frameshifts or superfluous stop
codons; the DNA associated with the purified full-length fusion was
amplified by PCR, then the three DNA fragments were cut by Ear I
restriction endonuclease and ligated to form the full length
template. The template was transcribed, ligated to
puromycin-containing DNA linkers, and translated to generate a
.sup.10Fn3-RNA/cDNA library, which was then reverse-transcribed to
yield the DNA-mRNA-peptide fusion library which was subsequently
used in the selection.
[0171] Selection for TNF-.alpha. binders took place in 50 mM HEPES,
pH 7.4, 0.02% Triton-X, 0.1 mg/mL salmon sperm DNA. The
PROfusion.TM. library was incubated with Sepharose-immobilized
TNF-.alpha.; after washing, the DNA associated with the tightest
binders was eluted with 0.1 M KOH, amplified by PCR, and
transcribed, ligated, translated, and reverse-transcribed into the
starting material for the next round of selection.
[0172] Ten rounds of such selection were performed (as shown in
FIG. 13); they resulted in a PROfusion.TM. pool that bound to
TNF-.alpha.-Sepharose with the apparent average K.sub.d of 120 nM.
Specific clonal components of the pool that were characterized
showed TNF-.alpha. binding in the range of 50-500 nM.
Immobilization, Target Protein Capture and MALDI-TOF Detection
[0173] As a first step toward immobilizing Fn3 fusions to a chip
surface, an oligonucleotide capture probe was prepared with an
automated DNA synthesizer (PE BioSystems Expedite 8909) using the
solid-support phosphoramidite approach. All reagents were obtained
from Glen Research. Synthesis was initiated with a solid support
containing a disuifide bond to eventually provide a 3'-terminal
thiol functionality. The first four monomers to be added were
hexaethylene oxide units, followed by 20 T monomers. The
5'-terminal DMT group was not removed. The capture probe was
cleaved from the solid support and deprotected with ammonium
hydroxide, concentrated to dryness in a vacuum centrifuge, and
purified by reverse-phase HPLC using an acetonitrile gradient in
triethylammonium acetate buffer. Appropriate fractions from the
HPLC were collected, evaporated to dryness in a vacuum centrifuge,
and the 5'-terminal DMT group was removed by treatment with 80%
AcOH for 30 minutes. The acid was removed by evaporation, and the
oligonucleotide was then treated with 100 mM DTT for 30 minutes to
cleave the disulfide bond. DTT was removed by repeated extraction
with EtOAc. The oligonucleotide was ethanol precipitated from the
remaining aqueous layer and checked for purity by reverse-phase
HPLC.
[0174] The 3'-thiol capture probe was adjusted to 250 .mu.M in
degassed 1.times.PBS buffer and applied as a single droplet (75
.mu.L) to a 9.times.9 mm gold-coated chip (Biacore) in an
argon-flushed chamber containing a small amount of water. After 18
hours at room temperature, the capture probe solution was removed,
and the functionalized chip was washed with 50 mL 1.times.PBS
buffer (2.times. for 15 minutes each) with gentle agitation, and
then rinsed with 50 mL water (2.times. for 15 minutes each) in the
same fashion. Remaining liquid was carefully removed and the
functionalized chips were either used immediately or stored at
4.degree. C. under argon.
[0175] About lpmol of .sup.10Fn3 fusion pool from the Round 10
TNF-.alpha. selection (above) was treated with RNAse A for several
hours, adjusted to 5.times.SSC in 70 .mu.L, and applied to a
functionalized gold chip from above as a single droplet. A 50 .mu.L
volume gasket device was used to seal the fusion mixture with the
functionalized chip, and the apparatus was continuously rotated at
4.degree. C. After 18 hours the apparatus was disassembled, and the
gold chip was washed with 50 mL 5.times.SSC for 10 minutes with
gentle agitation. Excess liquid was carefully removed from the chip
surface, and the chip was passivated with a blocking solution
(1.times.TBS+0.02% Tween-20+0.25% BSA) for 10 minutes at 4.degree.
C. Excess liquid was carefully removed, and a solution containing
500 .mu.g/mL TNF-.alpha. in the same composition blocking solution
was applied to the chip as a single droplet and incubated at
4.degree. C. for two hours with occasional mixing of the droplet
via Pipetman. After removal of the binding solution, the chip was
washed for 5 minutes at 4.degree. C. with gentle agitation (50 mL
1.times.TBS+0.02% Tween-20) and then dried at room temperature. A
second chip was prepared exactly as described above, except fusion
was not added to the hybridization mix.
[0176] Next, MALDI-TOF matrix (15 mg/mL
3,5-dimethoxy-4-hydroxycinnamic acid in 1:1 ethanol/10% formic acid
in water) was uniformly applied to the gold chips with a
high-precision 3-axis robot (MicroGrid, BioRobotics). A 16-pin tool
was used to transfer the matrix from a 384-well microtiter plate to
the chips, producing 200 micron diameter features with a 600 micron
pitch. The MALDI-TOF mass spectrometer (Voyager DE,
PerSeptive-Biosystems) instrument settings were as follows:
Accelerating Voltage=25k, Grid Voltage=92%, Guide Wire
Voltage=0.05%, Delay=200 on, Laser Power=2400, Low Mass Gate=1500,
Negative Ions=off. The gold chips were individually placed on a
MALDI sample stage modified to keep the level of the chip the same
as the level of the stage, thus allowing proper flight distance.
The instrument's video monitor and motion control system were used
to direct the laser beam to individual matrix features.
[0177] FIGS. 14 and 15 show the mass spectra from the .sup.10Fn3
fusion chip and the non-fusion chip, respectively. In each case, a
small number of 200 micron features were analyzed to collect the
spectra, but FIG. 15 required significantly more acquisitions. The
signal at 17.4 kDa corresponds to TNF-.alpha. monomer.
Immobilization, Target Protein Capture, and Fluorescence
Detection
[0178] Pre-cleaned 1.times.3 inch glass microscope slides
(Goldseal, #3010) were treated with Nanostrip (Cyantek) for 15
minutes, 10% aqueous NaOH at 70.degree. C. for 3 minutes, and 1%
aqueous HCl for 1 minute, thoroughly rinsing with deionized water
after each reagent. The slides were then dried in a vacuum
desiccator over anhydrous calcium sulfate for several hours. A 1%
solution of aminopropytrimethoxysilane in 95% acetone/5% water was
prepared and allowed to hydrolyze for 20 minutes. The glass slides
were immersed in the hydrolyzed silane solution for 5 minutes with
gentle agitation. Excess silane was removed by subjecting the
slides to ten 5-minute washes, using fresh portions of 95%
acetone/5% water for each wash, with gentle agitation. The slides
were then cured by heating at 110.degree. C. for 20 minutes. The
silane treated slides were immersed in a freshly prepared 0.2%
solution of phenylene 1,4-diisothiocyanate in 90% DMF/10% pyridine
for two hours, with gentle agitation. The slides were washed
sequentially with 90% DMF/10% pyridine, methanol, and acetone.
After air drying, the functionalized slides were stored at
0.degree. C. in a vacuum desiccator over anhydrous calcium sulfate.
Similar results were obtained with commercial amine-reactive slides
(3-D Link, Surmodics).
[0179] Oligonucleotide capture probes were prepared with an
automated DNA synthesizer (PE BioSystems Expedite 8909) using
conventional phosphoramidite chemistry. All reagents were from Glen
Research. Synthesis was initiated with a solid support bearing an
orthogonally protected amino functionality, whereby the 3'-terminal
amine is not unmasked until final deprotection step. The first four
monomers to be added were hexaethylene oxide units, followed by the
standard A, G, C and T monomers. All capture oligo sequences were
cleaved from the solid support and deprotected with ammonium
hydroxide, concentrated to dryness, precipitated in ethanol, and
purified by reverse-phase HPLC using an acetonitrile gradient in
triethylammonium acetate buffer. Appropriate fractions from the
HPLC were collected, evaporated to dryness in a vacuum centrifuge,
and then coevaporated with a portion of water.
[0180] The purified, amine-labeled capture oligos were adjusted to
a concentration of 250 .mu.M in 50 mM sodium carbonate buffer (pH
9.0) containing 10% glycerol. The probes were spotted onto the
amine-reactive glass surface at defined positions in a
5.times.5.times.6 array pattern with a 3-axis robot (MicroGrid,
BioRobotics). A 16-pin tool was used to transfer the liquid from
384-well microtiter plates, producing 200 micron features with a
600 micron pitch. Each sub-grid of 24 features represents a single
capture probe (i.e., 24 duplicate spots). The arrays were incubated
at room temperature in a moisture-saturated environment for 12-18
hours. The attachment reaction was terminated by imnersing the
chips in 2% aqueous ammonium hydroxide for five minutes with gentle
agitation, followed by rinsing with distilled water (3.times. for 5
minutes each). The array was finally soaked in 10.times.PBS
solution for 30 minutes at room temperature, and then rinsed again
for 5 minutes in distilled water.
[0181] Specific and thermodynamically isoenergetic sequences along
the .sup.10Fn3 mRNA were identified to serve as capture points to
self-assemble and anchor the .sup.10Fn3 protein. The software
program HybSimulator v4.0 (Advanced Gene Computing Technology,
Inc.) facilitated the identification and analysis of potential
capture probes. Six unique capture probes were chosen and printed
onto the chip, three of which are complementary to common regions
of the .sup.10Fn3 fusion pool's mRNA (CP3', CP5', and CPflag). The
remaining three sequences (CPneg1, CPneg2, and CPneg3) are not
complementary and function in part as negative controls. Each of
the capture probes possesses a 3'-amino terminus and four
hexaethylene oxide spacer units, as described above. The following
is a list of the capture probe sequences that were employed
(5'-3'): TABLE-US-00004 CP3': TGTAAATAGTAATTGTCCC (SEQ ID NO: 22)
CP5': TTTTTTTTTTTTTTTTTTTT (SEQ ID NO: 23) CPneg1: CCTGTAGGTGTCCAT
(SEQ ID NO: 24) CPflag: CATCGTCCTTGTAGTC (SEQ ID NO: 25) CPneg2:
CGTCGTAGGGGTA (SEQ ID NO: 26) CPneg3: CAGGTCTTCTTCAGAGA (SEQ ID NO:
27)
About lpmol of .sup.10Fn3 fusion pool from the Round 10 TNF-.alpha.
selection was adjusted to 5.times.SSC containing 0.02% Tween-20 and
2 mM vanadyl ribonucleotide complex in a total volume of 350 .mu.L.
The entire volume was applied to the microarray under a 400 .mu.L
gasket device and the assembly was continuously rotated for 18
hours at room temperature. After hybridization the slide was washed
sequentially with stirred 500 mL portions of 5.times.SSC,
2.5.times.SSC, and 1.times.SSC for 5 minutes each. Traces of liquid
were removed by centrifugation and the slide was allowed to
air-dry.
[0182] Recombinant human TNF-.alpha. (500 .mu.g, lyophilized, from
PreproTech) was taken up in 230 .mu.L 1.times.PBS and dialyzed
against 700 mL stirred 1.times.PBS at 4.degree. C. for 18 hours in
a Microdialyzer unit (3,500 MWCO, Pierce). The dialyzed TNF-.alpha.
was treated with EZ-Link NHS-LC-LC biotinylation reagent (20 .mu.g,
Pierce) for 2 hours at 0.degree. C., and again dialyzed against 700
mL stirred 1.times.PBS at 4.degree. C. for 18 hours in a
Microdialyzer unit (3,500 MWCO, Pierce). The resulting conjugate
was analyzed by MALDI-TOF mass spectrometry and was found to be
almost completely functionalized with a single biotin moiety.
[0183] Each of the following processes was conducted at 4.degree.
C. with continuous rotation or mixing. The protein microarray
surface was passivated by treatment with 1.times.TBS containing
0.02% Tween-20 and 0.2% BSA (200 .mu.L) for 60 minutes.
Biotinylated TNF-.alpha. (100 nM concentration made up in the
passivation buffer) was contacted with the microarray for 120
minutes. The microarray was washed with 1.times.TBS containing
0.02% Tween-20 (3.times.50 mL, 5 minutes each wash). Fluorescently
labeled streptavidin (2.5 .mu.g/mL Alexa 546-streptavidin conjugate
from Molecular Probes, made up in the passivation buffer) was
contacted with the microarray for 60 minutes. The microarray was
washed with 1.times.TBS containing 0.02% Tween-20 (2.times.50 mL, 5
minutes each wash) followed by a 3 minute rinse with 1.times.TBS.
Traces of liquid were removed by centrifugation, and the slide was
allowed to air-dry at room temperature.
[0184] Fluorescence laser scanning was performed with a GSI
Lumonics ScanArray 5000 system using 10 .mu.M pixel resolution and
preset excitation and emission wavelengths for Alexa 546 dye.
Phosphorimage analysis was performed with a Molecular Dynamics
Storm system. Exposure time was 48 hours with direct contact
between the microarray and the phosphor storage screen.
Phosphorimage scanning was performed at the 50 micron resolution
setting, and data was extracted with ImageQuant v.4.3 software.
[0185] FIGS. 16 and 17 are the phosphorimage and fluorescence scan,
respectively, of the same array. The phosphorimage shows where the
.sup.10Fn3 fusion hybridized based on the .sup.35S methionine
signal. The fluorescence scan shows where the labeled TNF-.alpha.
bound.
Sequence CWU 1
1
202 1 122 DNA Homo sapiens 1 ggaattccta atacgactca ctatagggac
aattactatt tacaattaca atgcatcacc 60 atcaccatca cgtttctgat
gttccgaggg acctggaagt tgttgctgcg acccccacca 120 gc 122 2 104 DNA
Homo sapiens 2 ggaattccta atacgactca ctatagggac aattactatt
tacaattaca atggtttctg 60 atgttccgag ggacctggaa gttgttgctg
cgacccccac cagc 104 3 126 DNA Homo sapiens misc_feature (1)...(126)
n = A,T,C or G misc_feature (1)...(126) s = C or G misc_feature 74,
75, 77, 78, 80, 81, 83, 84, 86, 87, 89, 90, 92, 93 n = A,T,C or G 3
agcggatgcc ttgtcgtcgt cgtccttgta gtcgctcttc cctgtttctc cgtaagtgat
60 cctgtaatat ctsnnsnnsn nsnnsnnsnn snnccagctg atcagtaggc
tggtgggggt 120 cgcagc 126 4 62 DNA Homo sapiens 4 agcggatgcc
ttgtcgtcgt cgtccttgta gtcgctcttc cctgtttctc cgtaagtgat 60 cc 62 5
99 DNA Homo sapiens 5 ggaattccta atacgactca ctatagggac aattactatt
tacaattaca atgcatcacc 60 atcaccatca cctcttcaca ggaggaaata gccctgtcc
99 6 132 DNA Homo sapiens misc_feature (1)...(132) n = A,T,C or G
misc_feature (1)...(132) s = C or G misc_feature 83, 84, 86, 87,
89, 90, 92, 93 n = A,T,C or G 6 agcggatgcc ttgtcgtcgt cgtccttgta
gtcgctcttc gtataatcaa ctccaggttt 60 aaggccgctg atggtagctg
tsnnsnnsnn snnaggcaca gtgaactcct ggacagggct 120 atttcctcct gt 132 7
64 DNA Homo sapiens 7 agcggatgcc ttgtcgtcgt cgtccttgta gtcgctcttc
gtataatcaa ctccaggttt 60 aagg 64 8 101 DNA Homo sapiens 8
ggaattccta atacgactca ctatagggac aattactatt tacaattaca atgcatcacc
60 atcaccatca cctcttctat accatcactg tgtatgctgt c 101 9 114 DNA Homo
sapiens misc_feature (1)...(114) n = A,T,C or G misc_feature
(1)...(114) s = C or G misc_feature 59, 60, 62, 63, 65, 66, 68, 69,
71, 72, 74, 75, 77, 78, 80, 81, 83, 84, 86, 87 n = A,T,C or G 9
agcggatgcc ttgtcgtcgt cgtccttgta gtctgttcgg taattaatgg aaattggsnn
60 snnsnnsnns nnsnnsnnsn nsnnsnnagt gacagcatac acagtgatgg tata 114
10 57 DNA Homo sapiens 10 agcggatgcc ttgtcgtcgt cgtccttgta
gtctgttcgg taattaatgg aaattgg 57 11 45 DNA T7 phage and tobacco
mosaic virus 11 gcgtaatacg actcactata gggacaatta ctatttacaa ttaca
45 12 33 DNA Artificial Sequence Flag sequence 12 agcggatgcc
ttgtcgtcgt cgtccttgta gtc 33 13 19 DNA Artificial Sequence Splint
oligonucleotide misc_feature (1)...(19) n = A,T,C or G misc_feature
10 n = A,T,C or G 13 tttttttttn agcggatgc 19 14 20 DNA Artificial
Sequence Puromycin linker oligonucleotide 14 aaaaaaaaaa aaaaaaaacc
20 15 30 DNA Mus musculus 15 gcggcagggt ttgcttactg gggccaaggg 30 16
27 DNA Mus musculus 16 gggaggggtg gaggtaggtc acagtcc 27 17 30 DNA
Mus musculus 17 tttgctagct ttaccaggag agtgggaggc 30 18 33 DNA Mus
musculus 18 aaaaagcttg ccaaaacgac acccccatct gtc 33 19 33 DNA Mus
musculus 19 catatggttt ctgatattcc gagagatctg gag 33 20 43 DNA Mus
musculus 20 catatgcatc accatcacca tcacgtttct gatattccga gag 43 21
30 DNA Mus musculus 21 gaattcctat gttttataat tgatggaaac 30 22 19
DNA Homo sapiens 22 tgtaaatagt aattgtccc 19 23 20 DNA Homo sapiens
23 tttttttttt tttttttttt 20 24 15 DNA Artificial Sequence
Oligonucleotide 24 cctgtaggtg tccat 15 25 16 DNA Homo sapiens 25
catcgtcctt gtagtc 16 26 13 DNA Artificial Sequence Oligonucleotide
26 cgtcgtaggg gta 13 27 17 DNA Artificial Sequence Oligonucleotide
27 caggtcttct tcagaga 17 28 24 DNA Homo sapiens 28 catatggttt
ctgatgttcc gagg 24 29 32 DNA Homo sapiens 29 gaattcctat gttcggtaat
taatggaaat tg 32 30 19 DNA Artificial Sequence DNA splint
Oligonucleotide misc_feature 10 n = A,T,C or G 30 tttttttttn
agcggatgc 19 31 7 PRT Homo sapien 31 Asn Arg Ser Gly Leu Gln Ser 1
5 32 10 PRT Homo sapien 32 Ala Gln Thr Gly His His Leu His Asp Lys
1 5 10 33 94 PRT Homo sapien 33 Val Ser Asp Val Pro Arg Asp Leu Glu
Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Asp
Ala Pro Ala Val Thr Val Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly
Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro
Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly
Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg Gly Asp 65 70
75 80 Ser Pro Ala Ser Ser Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90
34 95 PRT Homo sapiens 34 Val Ser Glu Ile Pro Arg Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Phe Ser Trp Asp Ala
Pro Ala Val Thr Val Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu
Thr Gly Gly Asn Ser Leu Val Gln Glu Phe 35 40 45 Thr Val Pro Gly
Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val
Asp Tyr Asn Thr Ile Thr Gly Tyr Ala Val Thr Thr Thr Tyr 65 70 75 80
Arg Thr Arg Ile Asp Lys Gln Pro Ile Ser Ile Asn Tyr Arg Thr 85 90
95 35 90 PRT Homo sapien 35 Val Ser Asp Val Pro Arg Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Asp Ala
Pro Ala Val Thr Val Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu
Lys Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Glu
Leu Asn Pro Thr Ala Thr Ile Ser Arg Leu Lys Pro 50 55 60 Gly Val
Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gln Asn Gly Thr 65 70 75 80
Pro Arg Arg His Leu Arg Pro Asn Phe His 85 90 36 95 PRT Homo sapien
36 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr
1 5 10 15 Gly Leu Leu Ile Ser Trp Asn Lys Ser Arg Met Thr Thr Arg
Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro
Val Gln Glu Phe 35 40 45 Thr Val Pro Val Thr Asp Ser Thr Ala Thr
Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Asn Thr Ile Ile
Val His Ala Val Thr Leu Thr Asn 65 70 75 80 Gln Asn Ser Asp His Thr
Tyr Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 95 37 91 PRT Homo sapien
37 Val Ser Asp Val Pro Arg Asp Leu Asp Val Val Ala Ala Thr Pro Thr
1 5 10 15 Ser Leu Leu Ile Ser Trp Asp Ser Ser His Arg Tyr Tyr Arg
Ile Thr 20 25 30 Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu
Phe Thr Ala Pro 35 40 45 Asn Asn Pro Pro Thr Ala Thr Ile Ser Gly
Leu Lys Pro Gly Val Asp 50 55 60 Tyr Thr Ile Thr Val Tyr Ala Val
Thr Pro Asp Gly Ser Arg His Met 65 70 75 80 Leu Thr Lys Pro Ile Ser
Ile Asn Tyr Arg Thr 85 90 38 88 PRT Homo sapiens 38 Val Ser Asp Val
Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu
Leu Ile Ser Trp His Asn Asn His Ile Asp Met Arg Tyr Tyr 20 25 30
Arg Ser Ala Asn Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Val Phe 35
40 45 Thr Val Pro Gln Arg Arg Gln Thr Ala Thr Ile Ser Gly Leu Lys
Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Pro
Lys Asn Gln 65 70 75 80 Gly Arg Arg Arg Gln Gly Ile Arg 85 39 94
PRT Homo sapiens 39 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala
Ala Thr Ser Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Arg Thr Pro Ala
Ser Pro His Gly Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly
Gly Asn Ser Pro Val Glu Glu Phe 35 40 45 Thr Val Pro Leu Leu Trp
Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr
Thr Ile Thr Val Tyr Ala Val Thr Pro Thr His Met 65 70 75 80 Leu Lys
Pro Gln Ser Met Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 40 94 PRT
Homo sapien 40 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Arg Thr Pro Ala Ser
Pro His Gly Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Glu Glu Phe 35 40 45 Thr Val Pro Leu Leu Trp Pro
Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Ile Thr Val Tyr Ala Val Thr Pro Thr His Met 65 70 75 80 Leu Lys Pro
Gln Ser Met Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 41 94 PRT Homo
sapien 41 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Ala
Ser Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Arg Pro Asn Pro Arg Leu
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Gly Leu Phe Ser Thr
Ala Thr Ile Ser Gly Leu Asn Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Pro Lys Glu Thr 65 70 75 80 Ser Asn Ile Phe
Ile Ala Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 42 94 PRT Homo sapien
42 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Ser Thr
1 5 10 15 Cys Leu Leu Ile Ser Trp Arg Pro Asn Pro Arg Leu Ser Arg
Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro
Val Gln Glu Phe 35 40 45 Thr Val Pro Gly Leu Phe Ser Thr Ala Thr
Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val
Tyr Ala Val Thr Pro Lys Glu Thr 65 70 75 80 Ser Asn Ile Phe Ile Ala
Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 43 94 PRT Homo sapien 43 Val
Ser Asp Val Pro Arg Asp Pro Glu Val Val Ala Ala Thr Pro Thr 1 5 10
15 Ser Leu Leu Ile Ser Trp Asp Pro Asn Ile Arg Leu Arg Arg Tyr Tyr
20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln
Glu Phe 35 40 45 Thr Val Pro Gly Phe Phe Ser Thr Ala Thr Ile Ser
Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala
Val Thr Ala Ser Arg Asn 65 70 75 80 Glu Asp Thr Arg Phe Gly Pro Ile
Ser Ile Asn Tyr Arg Thr 85 90 44 94 PRT Homo sapiens 44 Val Ser Asp
Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser
Leu Leu Ile Ser Trp Phe Arg Ser Leu Gln Arg Asp Arg Asp Tyr 20 25
30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
35 40 45 Thr Val Pro Phe Arg Met Lys Thr Ala Thr Ile Ser Gly Leu
Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Ile Thr
Pro Pro Asp Lys 65 70 75 80 Met Glu Pro Pro Lys Gly Pro Ile Ser Ile
Asn Tyr Arg Thr 85 90 45 94 PRT Homo sapiens 45 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu
Ile Ser Trp Tyr Arg His Thr Tyr Arg Asp Arg Tyr Tyr 20 25 30 Arg
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Ser 35 40
45 Thr Val Pro Pro Trp Ala Thr Thr Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Thr Ile Ala Val Tyr Ala Val Thr Asp Thr
Gly Tyr 65 70 75 80 Asp Val His Thr Lys Arg Pro Ile Ser Ile Asn Tyr
Arg Thr 85 90 46 94 PRT Homo sapiens 46 Val Ser Asp Val Pro Arg Asp
Leu Glu Val Val Ala Ala Ala Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser
Trp Tyr Arg His Thr Tyr Arg Asp Arg Tyr Tyr 20 25 30 Arg Ile Thr
Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr
Val Pro Pro Trp Ala Thr Thr Ala Ala Ile Ser Gly Leu Lys Pro 50 55
60 Gly Val Asp Tyr Ala Ile Ala Val Tyr Ala Val Thr Asp Thr Gly Tyr
65 70 75 80 Asp Val His Thr Lys Arg Pro Ile Ser Ile Asn Tyr Arg Thr
85 90 47 94 PRT Homo sapiens 47 Val Ser Asp Val Pro Arg Asp Leu Glu
Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Gln Leu Ile Ser Trp Pro
Phe Gly Trp Tyr Pro Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly
Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro
Pro Trp Ala Arg Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly
Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Tyr Ser Asp 65 70
75 80 Phe Ser Gln Val His Thr Pro Asn Ser Ile Asn Tyr Arg Thr 85 90
48 93 PRT Homo sapiens 48 Val Ser Asp Val Pro Arg Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro
Gly Arg Thr Tyr Ser Arg Tyr Arg 20 25 30 Ile Thr Tyr Gly Glu Thr
Gly Gly Asn Ser Pro Val Gln Glu Phe Thr 35 40 45 Val Pro Pro Trp
Ala Asn Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly 50 55 60 Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Pro Leu Pro Ile Pro 65 70 75 80
Thr Leu Val His Gly Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 49 94 PRT
Homo sapiens 49 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Ala Ser Pro Pro Met
Trp Cys Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Gly Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Thr
Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Ile Thr Val Tyr Ala Val Thr Glu Tyr Leu Pro 65 70 75 80 Glu Trp Asn
Met Thr Gln Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 50 94 PRT Homo
sapiens 50 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Ala Ser Pro Pro Met Trp
Cys Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Thr Thr
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Met Tyr Ala Val Thr Glu Tyr Leu Pro 65 70 75 80 Glu Trp Asn Met
Thr Gln Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 51 93 PRT Homo
sapiens 51 Asn Thr Thr His Tyr Arg Lys Asn Asn Tyr Tyr Ala Thr Pro
Thr Ser 1 5 10 15 Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser
Arg Tyr Tyr Arg 20 25 30 Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser
Pro Val Gln Glu Phe Thr 35 40 45 Val Pro Pro Trp Ala Ser Ile Ala
Thr Ile Ser Gly Leu Lys Pro Gly 50 55 60 Val Asp Tyr Thr Ile Thr
Val Tyr Ala Val Thr Asp Lys Ser Asp Thr 65 70 75 80 Tyr Lys Tyr Asp
Asp Pro Ile Ser Ile Asn Tyr Arg
Thr 85 90 52 93 PRT Homo sapiens 52 Val Ser Asp Val Pro Arg Asp Leu
Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp
Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr
Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val
Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60
Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ser Ala Thr Arg 65
70 75 80 Thr Val Lys Arg Asp Pro Ile Ser Ile Asn Tyr Arg Thr 85 90
53 94 PRT Homo sapiens 53 Val Ser Asp Ala Pro Arg Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg
Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu
Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro
Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val
Asp Tyr Thr Ile Thr Met Tyr Ala Val Thr Ser Asn Val Gly 65 70 75 80
Arg Leu Asp Thr Arg Tyr Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 54 94
PRT Homo sapiens 54 Val Ser Asp Val Pro Arg Asp Leu Asp Val Val Ala
Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly
Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly
Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Glu Pro Pro Trp Ala
Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr
Thr Ile Thr Val Tyr Ala Val Thr Ser Asn Val Gly 65 70 75 80 Arg Leu
Asp Thr Arg Tyr Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 55 94 PRT
Homo sapiens 55 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu
Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser
Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Ile Thr Val Tyr Ala Val Thr Lys Glu Pro Gln 65 70 75 80 Arg His Ala
Leu Val Thr Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 56 94 PRT Homo
sapiens 56 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Glu Thr Pro Ser 65 70 75 80 Thr Lys Pro His
Asn Val Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 57 74 PRT Homo
sapiens 57 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn His Pro Gly Pro Phe
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Arg Thr
Ala Ile Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala 65 70 58 93 PRT Homo sapiens 58 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Thr Ser 1 5 10 15 Leu Leu Ile
Ser Trp Asp Tyr Asn Arg Thr Gly Asp Arg Tyr Tyr Arg 20 25 30 Ile
Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr 35 40
45 Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Gly Gly Leu Lys Pro Gly
50 55 60 Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ala Gln Thr
Gly His 65 70 75 80 His Leu His Asp Lys Pro Ile Ser Ile Asn Tyr Arg
Ser 85 90 59 94 PRT Homo sapiens 59 Val Ser Asp Val Pro Arg Asp Leu
Glu Val Val Ala Ala Thr Ser Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp
His Tyr Leu Arg Arg Gln Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr
Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val
Pro Pro Trp Ala Ser Ile Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60
Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ala Gln Thr Gly 65
70 75 80 His His Leu His Asp Glu Pro Ile Ser Ile Asn Tyr Arg Thr 85
90 60 94 PRT Homo sapiens 60 Val Ser Asp Val Pro Arg Asp Leu Gln
Ile Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Asp
Ile Ser Arg Tyr Lys His Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly
Glu Thr Gly Gly Asp Ser Pro Val Gln Glu Phe 35 40 45 Thr Ala Pro
Pro Trp Ala Ser Ile Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly
Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ala Gln Thr Gly 65 70
75 80 His His Leu His Asp Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90
61 93 PRT Homo sapiens 61 Val Ser Asp Val Pro Arg Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro
Thr Ser Asn Pro Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu
Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro
Trp Ala Ser Ile Thr Ile Gly Gly Leu Lys Pro Gly 50 55 60 Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Ala Gln Thr Gly His 65 70 75 80
His Leu His Asp Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 62 94 PRT
Homo sapiens 62 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Cys Trp Arg Pro Thr Ser Asn
Pro Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser
Ile Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Ile Thr Val Tyr Ala Val Thr Ala Gln Thr Gly 65 70 75 80 His His Leu
His Asp Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 63 94 PRT Homo
sapiens 63 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Thr Ser Asn Pro
Pro Arg Tyr Tyr 20 25 30 Arg Ile Ser Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Ala Gln Thr Gly 65 70 75 80 His His Leu His
Asp Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 64 94 PRT Homo
sapiens 64 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Gln Leu Ile Ser Trp Lys Thr Thr Asn Pro Thr
Ala Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Thr Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Asn Leu Thr Thr 65 70 75 80 Arg Arg Arg His
Arg Ala Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 65 94 PRT Homo
sapiens 65 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Thr Thr Arg His Ser Pro
Val Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Ile Val Pro Pro Trp Ala Thr Thr
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Met Pro Thr Asn 65 70 75 80 Trp Arg Phe Pro
His Arg Pro Ile Ser Ile Asp Tyr Arg Thr 85 90 66 90 PRT Homo
sapiens 66 Val Ser Asp Val Pro Arg Asp Leu Glu Ala Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Leu Leu Ile Arg Glu Arg Glu Arg Arg Tyr Tyr
Arg Ile Thr Tyr 20 25 30 Gly Glu Thr Gly Gly Asn Ser Pro Val Gln
Glu Phe Thr Val Pro Gly 35 40 45 Ser Lys Ser Thr Ala Thr Ile Ser
Gly Leu Glu Pro Gly Val Asp Tyr 50 55 60 Thr Ile Thr Val Tyr Ala
Val Thr Pro His His Gly His Phe Asp Leu 65 70 75 80 Glu Leu Pro Ile
Ser Ile Asn Tyr Arg Thr 85 90 67 94 PRT Homo sapiens 67 Val Ser Asp
Val Pro Arg Asp Leu Glu Gly Val Ala Ala Thr Pro Thr 1 5 10 15 Ser
Leu Leu Ile Ser Arg Lys Asp Arg Val Ser Ser Arg Arg Tyr Tyr 20 25
30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
35 40 45 Thr Val Pro Gly Ser Lys Ser Thr Ala Ile Ile Ser Gly Leu
Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Ala Tyr Val Val Thr
Pro His His Gly 65 70 75 80 His Phe Asp Leu Glu Leu Pro Ile Ser Ile
Asn Tyr Arg Thr 85 90 68 95 PRT Homo spiens 68 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu
Ile Ser Trp His Met Ala Thr Pro Asn Thr Arg Tyr Tyr 20 25 30 Arg
Thr Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40
45 Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Asn Thr Asn Thr Val Tyr Ala Val Thr Ser
Val Asn 65 70 75 80 Ala Phe Pro Tyr Glu Gly Met Pro Ile Ser Ile Asn
Tyr Arg Thr 85 90 95 69 94 PRT Homo sapiens 69 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Ala Thr 1 5 10 15 Ser Leu Leu
Ser Ser Trp Tyr Leu Cys Thr Gly Asn Asn Arg Asp Tyr 20 25 30 Arg
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Ala Phe 35 40
45 Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Ile Pro Ser Arg Cys Met Leu Ser Leu Ala
Ser Leu 65 70 75 80 Met Ser Thr Arg Asn Lys Pro Ile Ser Ile Asn Tyr
Arg Thr 85 90 70 94 PRT Homo sapiens 70 Val Ser Asp Val Pro Arg Asp
Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser
Trp Arg Thr Pro Ala Ser Pro His Gly Tyr Tyr 20 25 30 Arg Ile Thr
Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Glu Glu Phe 35 40 45 Thr
Val Pro Leu Leu Trp Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55
60 Gly Val Asp Tyr Ala Ile Thr Val Tyr Ala Val Thr Pro Thr His Met
65 70 75 80 Leu Lys Pro Leu Ser Met Pro Ile Ser Ile Asn Tyr Arg Thr
85 90 71 93 PRT Homo sapiens 71 Ile Ser Asp Val Pro Arg Asp Met Glu
Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Asn
Met Ala His Pro His Asp Arg Asn Tyr 20 25 30 Arg Ile Thr Tyr Gly
Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Ser 35 40 45 Thr Val Pro
Arg Tyr Leu Ser Thr Ala Thr Ile Ser Gly Pro Lys Arg 50 55 60 Val
Asp Tyr Thr Ile Ile Val Tyr Ala Val Asn Gln Pro Thr Val Ser 65 70
75 80 Ala His Asn His Ala Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 72
93 PRT Homo sapiens 72 Val Ser Asp Val Pro Arg Asp Leu Lys Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Phe Pro Asp
Asn Ala Thr Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr
Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Leu Phe
Thr Thr Ala Thr Ile Ser Gly Leu Lys Pro Gly 50 55 60 Val Asp Tyr
Thr Ile Thr Val Tyr Ala Val Thr Ser His Arg Asp Tyr 65 70 75 80 His
Ser Thr Gly Arg Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 73 95 PRT
Homo sapiens 73 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Met Leu Leu Arg Asp
Asp Arg Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Thr Phe His Pro
Thr Ala Thr Ile Ser Gly Arg Lys Pro 50 55 60 Gly Val Asp Tyr Asn
Thr Ile Thr Val Tyr Ala Val Thr Gln Ser Thr 65 70 75 80 Asn Gly Asn
Arg Asn Asp Phe Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 95 74 94 PRT
Homo sapiens 74 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Ser Pro Pro Asn Asp
Ala His Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Gly Ser Lys Ser
Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Asn Thr Val Tyr Ala Val Thr Asp Gln Gln Ser 65 70 75 80 Tyr Thr Tyr
Tyr Ser Asn Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 75 94 PRT Homo
sapiens 75 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Leu Val Ile Ser Trp Ser Pro Pro Asn Asp Ala
His Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Gly Ser Lys Ser Thr
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Asn
Thr Val Tyr Ala Val Thr Asp Gln Gln Ser 65 70 75 80 Tyr Thr Tyr Tyr
Ser Asn Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 76 92 PRT Homo
sapiens 76 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Ser Pro Pro Asn Asp Ala
His Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Thr Thr
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Thr Met Pro Thr Asn Trp Arg 65 70 75 80 Phe Pro His Arg
Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 77 94 PRT Homo sapiens 77 Val
Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10
15 Ser Gln Leu Ile Ser Trp Thr Thr Arg His Ser Pro Val Arg Tyr Tyr
20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln
Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Thr Thr Ala Thr Ile Ser
Gly Leu Lys Pro 50 55 60 Gly Val
Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Met Pro Thr Asn 65 70 75 80
Trp Arg Phe Pro His Arg Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 78 94
PRT Homo sapiens 78 Val Ser Asp Val Pro Arg Asp Leu Glu Ile Val Ala
Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly
Leu Gln Ser Gly Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly
Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala
Ser Ile Ala Thr Thr Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr
Thr Ile Thr Val Tyr Ala Val Thr Ser Asn Val Gly 65 70 75 80 Arg Leu
Asp Thr Arg Tyr Pro Ile Ser Thr Asn Tyr Arg Thr 85 90 79 93 PRT
Homo sapiens VARIANT 17, 30, 34 Xaa = Any Amino Acid 79 Val Ser Asp
Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Xaa
Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Xaa Tyr Tyr 20 25
30 Arg Xaa Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
35 40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Ile Ser Gly Leu Lys
Pro Gly 50 55 60 Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ser
Asn Val Gly Arg 65 70 75 80 Leu Asp Thr Arg Tyr Pro Ile Phe Ile Asn
Tyr Arg Thr 85 90 80 76 PRT Homo sapiens 80 Val Ser Asp Val Pro Arg
Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile
Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile
Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45
Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50
55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr 65 70 75 81
94 PRT Homo sapiens 81 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser
Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr
Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp
Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Lys Ser Asp 65 70 75 80 Thr
Tyr Lys Tyr Asp Asp Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 82 94 PRT
Homo sapiens 82 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Cys Asn Arg Ser Gly Leu
Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser
Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Ile Thr Val Tyr Ala Val Thr Asp Lys Ser Asp 65 70 75 80 Thr Tyr Lys
Tyr Asp Asp Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 83 94 PRT Homo
sapiens 83 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Ser
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Pro Thr His Asn 65 70 75 80 Trp Asn Asp Gln
Thr Arg Ser Ile Ser Ile Asn Tyr Arg Thr 85 90 84 94 PRT Homo
sapiens 84 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Thr Ser Asn Pro
Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Ala Gln Thr Gly 65 70 75 80 Tyr His Leu His
Asp Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 85 93 PRT Homo
sapiens VARIANT 28, 51, 82 Xaa = Any Amino Acid 85 Val Ser Asp Val
Pro Arg Asp Leu Glu Val Val Ala Ala Pro Thr Ser 1 5 10 15 Arg Leu
Ile Ser Trp Arg Pro Gly Arg Thr Tyr Xaa Arg Tyr Tyr Arg 20 25 30
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr 35
40 45 Val Pro Xaa Trp Ala Asn Thr Ala Thr Ile Ser Gly Leu Lys Pro
Gly 50 55 60 Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Phe Pro
Pro Gly Tyr 65 70 75 80 Pro Xaa Thr Glu Met Pro Ile Ser Ile Asn Tyr
Arg Thr 85 90 86 92 PRT Homo sapiens 86 Ile Ser Asp Val Pro Arg Asp
Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser
Trp Arg Arg Trp Pro His Phe Asp Arg Tyr Tyr 20 25 30 Arg Ile Thr
Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr
Val Pro Pro Trp Ala Thr Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55
60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asn Pro Leu Ser
65 70 75 80 Pro Thr Thr Leu His Pro Pro Ile Asn Tyr Arg Thr 85 90
87 94 PRT Homo sapiens 87 Val Ser Asp Val Pro Arg Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Lys Pro
Arg Arg Thr Asn Thr Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu
Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro
Trp Gly Thr Ile Ala Thr Ile Asn Gly Leu Lys Pro 50 55 60 Gly Val
Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Leu Gly Thr Gly 65 70 75 80
Val Tyr Thr Arg Ala Gln Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 88 94
PRT Homo sapiens 88 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala
Ala Thr Pro Thr 1 5 10 15 Ser Gln Leu Ile Ser Trp Pro Phe Gly Trp
Tyr Pro Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly
Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala
Arg Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr
Thr Ile Thr Val Tyr Ala Val Thr His Phe Pro Glu 65 70 75 80 Ser Arg
Arg Pro Ala Lys Pro Met Ser Ile Asn Tyr Arg Thr 85 90 89 94 PRT
Homo sapiens 89 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp His Thr Glu Arg Ser
Phe Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Gly Ser
Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr
Ile Thr Val Tyr Ala Val Thr Glu His Tyr Arg 65 70 75 80 Asp Thr Gly
Thr Gly His Pro Ile Pro Ile Asn Tyr Arg Thr 85 90 90 94 PRT Homo
sapiens 90 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp His Thr Glu Arg Ser Phe
Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Gly Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Glu His Tyr Arg 65 70 75 80 Asp Thr Gly Thr
Gly His Pro Ile Pro Ile Asn Tyr Arg Thr 85 90 91 94 PRT Homo
sapiens 91 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Gln Leu Ile Ser Trp Lys Ser His Thr Phe His
Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Thr
Ala Ala Ile Ser Gly Leu Lys Pro 50 55 60 Gly Ala Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Leu Asn Arg Ser 65 70 75 80 Ser Pro Asn Ser
Ala Arg Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 92 94 PRT Homo
sapiens 92 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Arg Pro Gln Val Val Ser
Thr Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Asn His Lys Ala 65 70 75 80 Asn His His Asp
Ala Glu Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 93 94 PRT Homo
sapiens 93 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Thr Ser Asn His
Pro Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Thr Thr Asn Glu 65 70 75 80 Asp His Val Tyr
Ala Leu Pro Ile Ser Ile Asn Tyr Arg Ile 85 90 94 94 PRT Homo
sapiens 94 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Leu 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Asp Lys Ser Asp 65 70 75 80 Thr Tyr Lys Tyr
Asp Asp Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 95 94 PRT Homo
sapiens 95 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Gly Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Asp Met Ser Asp 65 70 75 80 Thr Tyr Lys Tyr
Asp Asp Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 96 94 PRT Homo
sapiens VARIANT 40 Xaa = Any Amino Acid 96 Val Ser Asp Val Pro Arg
Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile
Ser Trp Asp Thr His Asn Ala Tyr Asn Gly Tyr Tyr 20 25 30 Arg Ile
Thr Tyr Gly Glu Thr Xaa Gly Asn Ser Pro Val Arg Glu Phe 35 40 45
Thr Val Pro His Pro Glu Val Thr Ala Thr Ile Ser Gly Leu Lys Pro 50
55 60 Gly Val Asp Asp Thr Ile Thr Val Tyr Ala Val Thr Asn His His
Met 65 70 75 80 Pro Leu Arg Ile Phe Gly Pro Ile Ser Ile Asn His Arg
Thr 85 90 97 94 PRT Homo sapiens VARIANT 13, 21 Xaa = Any Amino
Acid 97 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Xaa Thr Pro
Thr 1 5 10 15 Ser Leu Leu Ile Xaa Trp Thr Arg Thr Asn Ala Asn Thr
Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser
Pro Val Gln Glu Phe 35 40 45 Thr Ala Pro Asn Asn Pro Pro Thr Ala
Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr
Val Tyr Ala Val Thr Pro Asp Gly Ser 65 70 75 80 Arg His Met Leu Thr
Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 98 94 PRT Homo sapiens 98
Leu Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5
10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr
Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val
Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Ala Ile
Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr
Ala Val Thr Asp Lys Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro
Ile Ser Ile Asn Tyr Arg Thr 85 90 99 94 PRT Homo sapiens 99 Val Ser
Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15
Ser Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20
25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu
Leu 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly
Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val
Thr Asp Lys Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Ile Ser
Ile Asn His Arg Thr 85 90 100 94 PRT Homo sapiens 100 Val Ser Asp
Val Pro Arg Gly Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser
Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25
30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
35 40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu
Lys His 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr
Asp Lys Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Ile Ser Ile
Asn Tyr Arg Thr 85 90 101 94 PRT Homo sapiens 101 Val Ser Asp Val
Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg
Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30
Arg Ile Thr Tyr Gly Glu Thr Glu Gly Asn Ser Pro Val Gln Glu Phe 35
40 45 Thr Val Pro Pro Trp Ala Ser Met Ala Thr Ile Ser Gly Leu Lys
Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp
Lys Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Ile Ser Ile Asn
Tyr Arg Thr 85 90 102 94 PRT Homo sapiens 102 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu
Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40
45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Lys
Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Thr Ser Ile Asn Tyr
Arg Thr 85 90 103 94 PRT Homo sapiens 103 Val Ser Asp Val Pro Arg
Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg
Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30
Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35
40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys
Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Ala Asp
Lys Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Ile Ser Ile Asn
Tyr Arg Thr 85 90 104 94 PRT Homo sapiens 104 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu
Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40
45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Lys
Ser Asp 65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Ile Ser Ile Asn Tyr
Arg Thr 85 90 105 94 PRT Homo sapiens 105 Val Ser Asp Val Pro Arg
Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile
Ser Trp Asn Arg Ser Gly Leu Gln Cys Arg Tyr Tyr 20 25 30 Arg Ile
Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45
Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50
55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Gln Arg
Asp 65 70 75 80 Thr Tyr Arg Tyr Asp Asp Pro Ile Ser Thr Asn Cys Arg
Thr 85 90 106 94 PRT Homo sapiens 106 Val Ser Asp Val Pro Arg Asp
Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser
Trp Arg Asn Ile Tyr Pro Ile Ala Arg Tyr Tyr 20 25 30 Arg Ile Thr
Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr
Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55
60 Gly Ala Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Lys Ser Asp
65 70 75 80 Thr Tyr Lys Tyr Asp Asp Pro Ile Ser Ile Asn Tyr Arg Thr
85 90 107 92 PRT Homo sapiens VARIANT 27 Xaa = Any Amino Acid 107
Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Ala Thr 1 5
10 15 Ser Gln Leu Ile Ser Trp Pro Trp Pro Ser Xaa Pro Thr Arg Tyr
Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Glu Gly Asn Ser Pro Val
Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Thr Ala Thr Ile
Ser Gly Ile Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Ala Val Tyr
Ala Val Thr Met Pro Glu Arg 65 70 75 80 Lys Tyr Asp Lys Pro Ile Ser
Ile Asn Tyr Arg Thr 85 90 108 94 PRT Homo sapiens 108 Val Ser Asp
Val Ser Arg Asp Leu Glu Ala Val Ala Ala Thr Pro Thr 1 5 10 15 Ser
Leu Leu Ile Ser Trp Asn Pro Asn Arg Ser Phe Ala Arg Tyr Tyr 20 25
30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
35 40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Gly Gly Leu
Lys Pro 50 55 60 Arg Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr
Ala Gln Thr Gly 65 70 75 80 His His Leu His Asp Lys Ser Ile Pro Ile
Asn Tyr Arg Thr 85 90 109 94 PRT Homo sapiens 109 Val Ser Asp Val
Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg
Leu Ile Ser Trp Arg Pro Gly Arg Thr Tyr Ser Arg Tyr Tyr 20 25 30
Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Ser 35
40 45 Thr Val Pro Pro Trp Ala Asn Thr Ala Thr Ile Ser Gly Leu Lys
Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Phe
Pro Pro Gly 65 70 75 80 Tyr Pro Leu Thr Glu Met Pro Ile Ser Ile Asn
Tyr Arg Thr 85 90 110 94 PRT Homo sapiens 110 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Ser 1 5 10 15 Ser Arg Leu
Ile Ser Trp Arg Pro Gly Arg Thr Tyr Ser Arg Tyr Tyr 20 25 30 Arg
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40
45 Thr Val Pro Pro Trp Ala Asn Thr Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Thr Ile Ala Val Tyr Ala Val Thr Phe Pro
Thr Gly 65 70 75 80 Tyr Pro Leu Thr Glu Met Pro Ile Ser Ile Asn Tyr
Arg Thr 85 90 111 94 PRT Homo sapiens 111 Val Ser Asp Val Pro Arg
Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile
Ser Trp Arg Pro Gly Arg Thr Tyr Ser Arg Tyr Tyr 20 25 30 Arg Ile
Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45
Thr Val Pro Pro Trp Ala Asn Thr Ala Thr Ile Ser Gly Leu Lys Pro 50
55 60 Gly Val Asp Tyr Thr Ile Thr Ala Tyr Ala Val Thr Tyr Thr His
Ser 65 70 75 80 Thr Pro Met Gln Asp Glu Pro Ile Ser Ile Asn Tyr Arg
Thr 85 90 112 94 PRT Homo sapiens 112 Val Ser Asp Val Pro Arg Asp
Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser
Trp Asp Asn Ser Arg Pro Asn Thr Arg Tyr Tyr 20 25 30 Arg Ile Thr
Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr
Val Pro Pro Trp Gly Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55
60 Gly Val Lys Tyr Thr Ile Thr Val Tyr Ala Val Thr Thr Ser Glu Cys
65 70 75 80 His Lys Leu Ser Ser Thr Ser Ile Ser Ile Asn Tyr Arg Thr
85 90 113 91 PRT Homo sapiens 113 Val Ser Asp Val Pro Arg Asp Leu
Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp
Thr Arg Thr Asn Ala Ser Thr Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr
Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val
Pro Asn Phe Trp Trp Ile Ser Gly Leu Lys Pro Gly Val Asp 50 55 60
Tyr Thr Ile Thr Val Tyr Ala Val Ala Ser Pro Asp Glu Thr Ser Ala 65
70 75 80 Tyr Ser Glu Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 114 92
PRT Homo sapiens VARIANT 3, 18, 23 Xaa = Any Amino Acid 114 Val Ser
Xaa Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15
Ser Xaa Leu Ile Ser Trp Xaa Pro Arg Ser His His Asp Arg Tyr Tyr 20
25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu
Phe 35 40 45 Thr Val Pro Pro Trp Gly Thr Ile Ala Thr Ile Asp Gly
Leu Lys Pro 50 55 60 Gly Val Gly Tyr Thr Val Thr Val Tyr Ala Val
Thr Asp Asn Pro Asn 65 70 75 80 Ser Ala Lys Ala Gln His Pro Ile Asn
Ser Arg Thr 85 90 115 94 PRT Homo sapiens 115 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Val Ala Thr Pro Thr 1 5 10 15 Ser Gln Leu
Ile Ser Trp Met Thr Pro His Asn His Val Arg Tyr Tyr 20 25 30 Gly
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Ser 35 40
45 Thr Val Pro Thr Gly Asn Ala Thr Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Pro His
His Gly 65 70 75 80 His Phe Asp Leu Glu Pro Pro Ile Ser Ile Asn Tyr
Arg Thr 85 90 116 94 PRT Homo sapiens 116 Val Ser Asp Val Pro Arg
Asp Leu Glu Val Val Ala Ala Thr Ser Thr 1 5 10 15 Gly Leu Leu Ile
Ser Trp Arg Thr Pro Ala Ser Pro His Gly Tyr Tyr 20 25 30 Arg Ile
Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Glu Glu Phe 35 40 45
Thr Val Pro Leu Leu Trp Pro Thr Ala Thr Ile Ser Gly Leu Lys Pro 50
55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Pro Thr His
Met 65 70 75 80 Leu Lys Pro Gln Ser Met Pro Ile Ser Ile Asn Tyr Arg
Thr 85 90 117 94 PRT Homo sapiens 117 Val Ser Asp Val Pro Arg Asp
Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser
Trp Ser Pro Pro Asn Asp Ala His Arg Tyr Tyr 20 25 30 Arg Ile Thr
Tyr Gly Lys Thr Gly Gly Asp Ser Pro Val Gln Glu Phe 35 40 45 Thr
Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55
60 Gly Val Asp Tyr Thr Ser Val Val Tyr Ala Val Thr Asp Gln Gln Ser
65 70 75 80 Tyr Thr Tyr Tyr Ser Asn Pro Ile Ser Ile Asn Tyr Arg Thr
85 90 118 94 PRT Homo sapiens VARIANT 28 Xaa = Any Amino Acid 118
Val Ser Asp Val Pro Ser Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5
10 15 Ser Leu Leu Ile Ser Trp Glu Gln Ser Pro Thr Xaa Gly Arg Tyr
Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val
Gln Glu Phe 35 40 45 Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile
Ser Gly Arg Lys Pro 50 55 60 Gly Ala Asp Tyr Thr Ile Thr Val Tyr
Ala Val Thr Ile Glu Lys Asp 65 70 75 80 Arg Ile Pro Leu Phe Gly Pro
Ile Ser Ile Ser Tyr Arg Thr 85 90 119 94 PRT Homo sapiens 119 Val
Ser Asp Val Pro Ser Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10
15 Ser Leu Leu Ile Ser Trp Glu Gln Ser Pro Thr Tyr Gly Arg Tyr Tyr
20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln
Glu Phe 35 40 45 Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser
Gly Arg Lys Pro 50 55 60 Gly Ala Asp Tyr Thr Ile Thr Val Tyr Ala
Val Thr Ile Glu Lys Asp 65 70 75 80 Arg Ile Pro Leu Phe Gly Pro Ile
Ser Ile Ser Tyr Arg Thr 85 90 120 94 PRT Homo sapiens VARIANT 28
Xaa = Any Amino Acid 120 Val Ser Asp Val Pro Ser Asp Leu Glu Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Glu Gln
Ser Pro Thr Xaa Gly Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu
Thr Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Gly
Ser Lys Ser Thr Ala Thr Ile Ser Gly Arg Lys Pro 50 55 60 Gly Ala
Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ile Glu Lys Asp 65 70 75 80
Arg Ile Pro Leu Phe Gly Pro Ile Ser Ile Ser Tyr Arg Thr 85 90 121
94 PRT Homo sapiens 121 Val Pro Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Asp Thr His
Asn Ala Tyr Asn Gly Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr
Gly Gly Ser Ser Pro Ala Gln Glu Phe 35 40 45 Thr Val Pro His Pro
Glu Val Thr Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp
Asp Thr Ile Thr Val Tyr Ala Val Thr Ile His His Met 65 70 75 80 Pro
Leu Arg Ile Phe Gly Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 122 94
PRT Homo sapiens 122 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser
Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr
Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp
Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Glu Ser Asp 65 70 75 80 Thr
Tyr Lys Tyr Asp Asp Pro Val Ser Ile Asn Tyr Arg Thr 85 90 123 94
PRT Homo sapiens 123 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser
Gly Leu Gln Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr
Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp
Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Asp Glu Ser Asp 65 70 75 80 Thr
Tyr Lys Tyr Asp Asp Pro Val Ser Thr Asn Tyr Arg Thr 85 90 124 94
PRT Homo sapiens 124 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Asn Arg Ser
Gly Leu Gln Ser Gly Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr
Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp
Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Pro Asn Val Gly 65 70 75 80 Arg
Leu Asp Thr Arg Tyr Pro Ile Ser Ile Asp Cys Arg Thr 85 90 125 94
PRT Homo sapiens VARIANT 86 Xaa = Any Amino Acid 125 Val Ser Asp
Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser
Arg Leu Ile Ser Trp Asn Arg Ser Gly Leu Gln Ser Arg Tyr Tyr 20 25
30 Arg Thr Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe
35 40 45 Thr Val Pro Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu
Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr
Ser Asn Val Gly 65 70 75 80 Arg Leu Asp Thr Arg Xaa Pro Ile Ser Ile
Asn Tyr Arg Thr 85 90 126 94 PRT Homo sapiens VARIANT 75 Xaa = Any
Amino Acid 126 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala
Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Thr Met Pro Val
Thr Ala Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly
Asp Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser
Ile Ala Ala Ile Ser Gly Leu Lys Pro 50 55 60 Gly Ala Asp Tyr Thr
Ile Thr Val Tyr Ala Xaa Thr Ser Ala Thr Pro 65 70 75 80 Ser Arg Pro
Asn Val His Pro Ile Ser Ile Asn Leu Thr Thr 85 90 127 88 PRT Homo
sapiens 127 Val Ser Asp Val Pro Gly Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Leu Leu Ile Gly Trp Ser Met Thr Pro Asn Trp
Pro Arg Tyr Tyr 20 25 30 Arg Ile Ala Tyr Gly Glu Thr Gly Gly Asp
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Ile Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr His Arg Asp Thr 65 70 75 80 Pro Ile Ser Ile
Asn Tyr Arg Thr 85 128 90 PRT Homo sapiens 128 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Val Ala Ala Thr Pro Ile 1 5 10 15 Ser Gln Leu
Thr Ser Trp Gln Pro Gln Pro Asn Gly Ser Arg Tyr Tyr 20 25 30 Arg
Ile Ala Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Arg Glu Phe 35
40 45 Thr Val Pro Ala Arg Glu Gln Thr Ala Thr Ser Gly Leu Lys Pro
Gly 50 55 60 Val Asp Tyr Ala Ile Thr Val Tyr Ala Ala Thr His Gly
Lys Pro Pro 65 70 75 80 His Ile His Phe Thr Ile Asn Tyr Arg Thr 85
90 129 94 PRT Homo sapiens VARIANT 2, 9, 12, 22 Xaa = Any Amino
Acid 129 Val Xaa Asp Val Pro Arg Asp Leu Xaa Val Val Xaa Ala Thr
Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Xaa Arg Ser Gly Asn Arg Thr
Thr Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Asp Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Met Pro Pro Trp Ala Thr Val
Ala Ala Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Thr His Asn Ser 65 70 75 80 Thr Ala Gln Pro
Glu Tyr Pro Ile Pro Phe Asn Arg Arg Thr 85 90 130 94 PRT Homo
sapiens 130 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Gly Arg Thr Tyr
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Asn Thr
Ala Thr Ile Ser Cys Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Ala Phe Pro Pro Gly 65 70 75 80 Tyr Pro Leu Thr
Glu Met Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 131 94 PRT Homo
sapiens 131 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Gly Arg Ala Tyr
Ser Arg Tyr Phe 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Asn Thr
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Ala Val Tyr Ala Val Thr Phe Pro Pro Arg 65 70 75 80 Tyr Pro Leu Thr
Glu Met Pro Ile Ser Ile Asn Tyr Arg Ala 85 90 132 94 PRT Homo
sapiens 132 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Gly Arg Thr Tyr
Ser Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Ala Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Ile
Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile
Thr Val Tyr Ala Val Thr Asp Lys Ser Gly 65 70 75 80 Thr Tyr Arg Tyr
Asp Asp Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 133 94 PRT Homo
sapiens 133 Val Ser Asp Val Pro Arg Asp Leu Arg Val Val Ala Ala Thr
Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Arg Pro Ala Ser Asn Pro
Ala Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn
Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Pro Trp Ala Ser Val
Ala Thr Ile Gly Gly Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Val
Thr Val Tyr Ala Val Thr Ala Gln Thr Gly 65 70 75 80 His Arg Leu His
Asp Lys Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 134 87 PRT Homo
sapiens 134 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr
Pro Ser 1 5 10 15 Leu Leu Ile Ser Trp Arg Pro Pro Ala Asp Leu Asn
Arg Tyr Tyr Arg 20 25 30 Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser
Pro Val Gln Glu Phe Thr 35 40 45 Val Pro Pro Trp Gly Thr Val Ala
Thr Val Asn Gly Leu Lys Pro Gly 50 55 60 Val Gly Tyr Thr Ile Thr
Val Tyr Ala Val Thr His Arg Asp Thr Pro 65 70 75 80 Ile Ser Ile Asn
Tyr Arg Ala 85 135 93 PRT Homo sapiens 135 Val Thr Asp Val Pro Arg
Gly Leu Lys Ile Val Ala Ala Thr Pro Ser 1 5 10 15 Leu Leu Ile Ser
Trp Arg Asn Ala Lys Asp Pro Gly Arg Tyr Tyr Arg 20 25 30 Ile Thr
Tyr Gly Glu Thr Gly Gly Ser Ser Pro Val Gln Glu Phe Thr 35 40 45
Val Pro Pro Trp Gly Thr Ile Ala Ala Ile Asn Gly Leu Lys Pro Gly 50
55 60 Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Ala Thr Asn Pro
Gly 65 70 75 80 Pro Thr Gln His Arg Pro Ile Pro Ile Asn Tyr Arg Thr
85 90 136 94 PRT Homo sapiens 136 Val Ser Asp Val Pro Arg Asp Leu
Glu Val Val Ala Ala Asp Pro His 1 5 10 15 Gln Pro Leu Ile Cys Trp
Ala Ser Pro Pro Met Trp Cys Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr
Gly Glu Ser Gly Gly Asn Ser Pro Val Gln Glu Phe 35 40 45 Thr Val
Pro Pro Trp Ala Thr Ala Ala Ala Ile Ser Gly Leu Lys Pro 50 55 60
Gly Val Asp Tyr Thr Ile Thr Val His Ala Val Thr Asp Glu Ser Trp 65
70 75 80 Ser Asp Arg Ser Met Asp Pro Ile Ser Ile Asn Cys Arg Thr 85
90 137 94 PRT Homo sapiens 137 Val Ser Asp Val Pro Arg Asp Leu Lys
Val Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Arg Leu Ile Ser Trp Thr
His Asp Asn Val Pro Ala Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly
Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Leu 35 40 45 Thr Val Pro
Pro Trp Ala Ser Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly
Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Leu Tyr Thr Gly 65 70
75 80 Asn His Arg Pro Glu His Pro Ile Ser Ile Asn Tyr Arg Thr 85 90
138 93 PRT Homo sapiens 138 Val Ser Asp Val Pro Arg Asp Pro Val Val
Val Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Tyr Arg
His Thr Tyr Arg Asp Arg Tyr Tyr 20 25 30 Arg Val Thr Tyr Gly Glu
Thr Arg Gly Asn Ser Pro Ile Arg Glu Phe 35 40 45 Thr Val Pro Pro
Trp Ala Thr Ile Ala Thr Ile Ser Gly Leu Lys Pro 50 55 60 Gly Val
Asp Tyr Thr Ile Ala Val Tyr Ala Val Thr Asp Ala Gly Tyr 65 70 75 80
Asp Val His Thr Lys Arg Pro Ile Ser Ile Asn Arg Thr 85 90 139 94
PRT Homo sapiens 139 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Gly Leu Leu Ile Ser Trp Arg Asn Asn
Gln Tyr Thr Pro Arg His Tyr 20 25 30 Gly Ile Thr Tyr Gly Glu Thr
Gly Gly Lys Ser Pro Val Gln Glu Phe 35 40 45 Thr Val Pro Glu Leu
Asn Pro Thr Ala Thr Ile Ser Arg Leu Lys Pro 50 55 60 Gly Val Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Gln Asn Gly Thr 65 70 75 80 Pro
Arg Val Ile Tyr Gly Pro Ile Ser Ile Asn Tyr Arg Thr 85 90 140 89
PRT Homo sapiens 140 Val Ser Asp Val Pro Arg Asp Leu Glu Val Val
Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu Asn Val Pro Ile Ile Arg
Tyr Tyr Arg Ile Thr Tyr Gly 20 25 30 Glu Thr Gly Gly Asn Ser Pro
Val Gln Glu Phe Thr Val Pro Ala Pro 35 40 45 Lys Ala Ile Ala Thr
Thr Ser Gly Leu Lys Pro Gly Val Asp Tyr Thr 50 55 60 Ile Thr Val
Tyr Gly Val Thr Ser His Arg Asn His Phe His Val Glu 65 70 75 80 Thr
Pro Ile Ser Ile Asn Tyr Gln Ala 85 141 21 PRT Homo sapiens 141 Asp
Ala Pro Ala Val Thr Val Gly Ser Lys Ser Gly Arg Gly Asp Ser 1 5 10
15 Pro Ala Ser Ser Lys 20 142 21 PRT Homo sapiens 142 Ala Ser Pro
Pro Met Trp Cys Pro Trp Ala Thr Glu Tyr Leu Pro Glu 1 5 10 15 Trp
Asn Met Thr Gln 20 143 21 PRT Homo sapiens 143 Asn Arg Ser Gly Leu
Gln Ser Pro Trp Ala Ser Asp Lys Ser Asp Thr 1 5 10 15 Tyr Lys Tyr
Asp Asp 20 144 21 PRT Homo sapiens 144 Arg Pro Thr Ser Asn Pro Pro
Pro Trp Ala Ser Ala Gln Thr Gly His 1 5 10 15 His Leu His Asp Lys
20 145 21 PRT Homo sapiens 145 His Thr Glu Arg Ser Phe Pro Pro Trp
Gly Ser Glu His Tyr Arg Asp 1 5 10 15 Thr Gly Thr Gly His 20 146 21
PRT Homo sapiens 146 Thr Thr Arg His Ser Pro Val Pro Trp Ala Thr
Met Pro Thr Asn Trp 1 5 10 15 Arg Phe Pro His Arg 20 147 21 PRT
Homo sapiens 147 Arg Pro Asn Pro Arg Leu Ser Gly Leu Phe Ser Pro
Lys Glu Thr Ser 1 5 10 15 Asn Ile Phe Ile Ala 20 148 21 PRT Homo
sapiens 148 Ser Pro Pro Asn Asp Ala His Gly Ser Lys Ser Asp Gln Gln
Ser Tyr 1 5 10 15 Thr Tyr Tyr Ser Asn 20 149 21 PRT Homo sapiens
149 Arg Thr Pro Ala Ser Pro His Leu Leu Trp Pro Pro Thr His Met Leu
1 5 10 15 Lys Pro Gln Ser Met 20 150 21 PRT Homo sapiens 150 Tyr
Arg His Thr Tyr Arg Asp Pro Trp Ala Thr Asp Thr Gly Tyr Asp 1 5 10
15 Val His Thr Lys Arg 20 151 21 PRT Homo sapiens 151 Asn Arg Ser
Gly Leu Gln Ser Pro Trp Ala Ser Ser Asn Val Gly Arg 1 5 10 15 Leu
Asp Thr Arg Tyr 20 152 21 PRT Homo sapiens 152 Asp Thr His Asn Ala
Tyr Asn His Pro Glu Val Asn His His Met Pro 1 5 10 15 Leu Arg Ile
Phe Gly 20 153 21 PRT Homo sapiens 153 Arg Pro Thr Ser Asn Pro Pro
Pro Trp Ala Ser Pro Val Tyr Pro Met 1 5 10 15 His Ser Met Leu Ser
20 154 21 PRT Homo sapiens 154 Arg Asn Ile Tyr Pro Ile Ala Pro Trp
Ala Ser Asp Lys Ser Asp Thr 1 5 10 15 Tyr Lys Tyr Asp Asp 20 155 21
PRT Homo sapiens 155 Asn Arg Ser Gly Leu Gln Cys Pro Trp Ala Ser
Asp Gln Arg Asp Thr 1 5 10 15 Tyr Lys Tyr Asp Asp 20 156 21 PRT
Homo sapiens 156 Arg Pro Gly Arg Thr Tyr Ser Pro Trp Ala Asn Phe
Pro Thr Gly Tyr 1 5 10 15 Pro Leu Thr Glu Met 20 157 21 PRT Homo
sapiens 157 Arg Pro Gly Arg Thr Tyr Ser Pro Trp Ala Asn Phe Pro Pro
Gly Tyr 1 5 10 15 Pro Leu Thr Glu Met 20 158 21 PRT Homo sapiens
158 Met Thr Pro His Asn His Val Thr Gly Asn Ala Pro His His Gly His
1 5 10 15 Phe Asp Leu Glu Pro 20 159 21 PRT Homo sapiens 159 Thr
Arg Thr Asn Ala Ser Thr Asn Phe Trp Trp Ser Pro Asp Glu Thr 1 5 10
15 Ser Ala Tyr Ser Glu 20 160 21 PRT Homo sapiens 160 Asn Arg Ser
Gly Leu Gln Ser Pro Trp Ala Ser Asp Lys Ser Asp Thr 1 5 10 15 Tyr
Lys Tyr Asp Asp 20 161 21 PRT Homo sapiens 161 Arg Pro Gly Arg Thr
Tyr Ser Pro Trp Ala Asn Tyr Thr His Ser Thr 1 5 10 15 Pro Met Gln
Asp Glu 20 162 21 PRT Homo sapiens 162 Arg Thr Pro Ala Ser Pro His
Leu Leu Trp Pro Pro Thr His Met Leu 1 5 10 15 Lys Pro Gln Ser Met
20 163 21 PRT Homo sapiens 163 Thr Arg Thr Asn Ala Asn Thr Asn Asn
Pro Pro Pro Asp Gly Ser Arg 1 5 10 15 His Met Leu Thr Lys 20 164 21
PRT Homo sapiens 164 Asp Asn Ser Arg Pro Asn Thr Pro Trp Gly Ser
Thr Ser Glu Cys His 1 5 10 15 Lys Leu Ser Ser Thr 20 165 21 PRT
Homo sapiens 165 Asn Pro Asn Arg Ser Phe Ala Pro Trp Ala Ser Ala
Gln Thr Gly His 1 5 10 15 His Leu His Asp Lys 20 166 15 PRT Homo
sapiens 166 Ser Met Thr Pro Asn Trp Pro Pro Trp Ala Ser His Arg Asp
Thr 1 5 10 15 167 21 PRT Homo sapiens 167 Asp Thr His Asn Ala Tyr
Asn His Pro Glu Val Ile His His Met Pro 1 5 10 15 Leu Arg Ile Phe
Gly 20 168 20 PRT Homo sapiens 168 Ala Ser Pro Pro Met Trp Pro Trp
Ala Thr Asp Glu Ser Trp Ser Asp 1 5 10 15 Arg Ser Met Asp 20 169 15
PRT Homo sapiens 169 Arg Pro Pro Ala Asp Leu Asn Pro Trp Gly Thr
His Arg Asp Thr 1 5 10 15 170 21 PRT Homo sapiens 170 Glu Gln Ser
Pro Thr Tyr Gly Gly Ser Lys Ser Ile Glu Lys Asp Arg 1 5 10 15 Ile
Pro Leu Phe Gly 20 171 21 PRT Homo sapiens 171 Arg Pro Gly Arg Thr
Tyr Ser Pro Trp Ala Asn Phe Pro Pro Gly Tyr 1 5 10 15 Pro Leu Thr
Glu Met 20 172 21 PRT Homo sapiens 172 Arg Pro Gly Arg Thr Tyr Ser
Pro Trp Ala Ser Asp Lys Ser Gly Thr 1 5 10 15 Tyr Arg Tyr Asp Asp
20 173 21 PRT Homo sapiens 173 Tyr Arg His Thr Tyr Arg Asp Pro Trp
Ala Thr Asp Ala Gly Tyr Asp 1 5 10 15 Val His Thr Lys Arg 20 174 21
PRT Homo sapiens 174 Arg Thr Met Pro Val Thr Ala Pro Trp Ala Ser
Ser Ala Thr Pro Ser 1 5 10 15 Arg Pro Asn Val His 20 175 21 PRT
Homo sapiens 175 Arg Pro Gly Arg Ala Tyr Ser Pro Trp Ala Asn Phe
Pro Pro Arg Tyr 1 5 10 15 Pro Leu Thr Glu Met 20 176 21 PRT Homo
sapiens 176 Ser Pro Pro Asn Asp Ala His Gly Ser Lys Ser Asp Gln Gln
Ser Tyr 1 5 10 15 Thr Tyr Tyr Ser Asn 20 177 16 PRT Homo sapiens
177 Ile Ile Ala Pro Lys Ala Ser His Arg Asn His Phe His Val Glu Thr
1 5 10 15 178 21 PRT Homo sapiens 178 Arg Asn Asn Gln Tyr Thr Pro
Glu Leu Asn Pro Gln Asn Gly Thr Pro 1 5 10 15 Arg Val Ile Tyr Gly
20 179 21 PRT Homo sapiens 179 Arg Pro Ala Ser Asn Pro Ala Pro Trp
Ala Ser Ala Gln Thr Gly His 1 5 10 15 Arg Leu His Asp Lys 20 180 21
PRT Homo sapiens 180 Asn Arg Ser Gly Leu Gln Ser Pro Trp Ala Ser
Pro Asn Val Gly Arg 1 5 10 15 Leu Asp Thr Arg Tyr 20 181 21 PRT
Homo sapiens 181 Asn Arg Ser Gly Leu Gln Ser Pro Trp Ala Ser Asp
Glu Ser Asp Thr 1 5 10 15 Tyr Lys Tyr Asp Asp 20 182 21 PRT Homo
sapiens 182 Thr His Asp Asn Val Pro Ala Pro Trp Ala Ser Leu Tyr Thr
Gly Asn 1 5 10 15 His Arg Pro Glu His 20 183 21 PRT Homo sapiens
183 Arg Ser Gly Asn Arg Thr Thr Pro Trp Ala Thr Thr His Asn Ser Thr
1 5 10 15 Ala Gln Pro Glu Tyr 20 184 21 PRT Homo sapiens 184 Asn
Arg Ser Gly Leu Gln Ser Pro Trp Ala Ser Ser Asn Val Gly Arg 1 5 10
15 Leu Asp Thr Arg Tyr 20 185 21 PRT Homo sapiens 185 Arg Asn Ala
Lys Asp Pro Gly Pro Trp Gly Thr Ala Thr Asn Pro Gly 1 5 10 15 Pro
Thr Gln His Arg 20 186 94 PRT Bovis taurus 186 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Ile Ala Ala Thr Pro Thr 1 5 10 15 Ser Leu Leu
Ile Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr 20 25 30 Arg
Ile Thr Tyr Gly Glu Thr Gly Gly Ser Ser Pro Val Gln Glu Phe 35 40
45 Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly Leu Lys Pro
50 55 60 Gly Val Asp Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg
Gly Asp 65 70 75 80 Ser Pro Ala Ser Ser Lys Pro Val Ser Ile Asn Tyr
Arg Thr 85 90 187 92 PRT Rattus norvegicus 187 Val Ser Asp Val Pro
Arg Asp Leu Glu Val Ile Ala Ser Thr Pro Thr 1 5 10 15 Ser Leu Leu
Ile Ser Trp Glu Pro Ala Val Ser Val Arg Tyr Tyr Arg 20 25 30 Ile
Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu
Phe Thr 35 40 45 Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Asn Ile
Lys Pro Gly Ala 50 55 60 Asp Tyr Thr Ile Thr Leu Tyr Ala Val Thr
Gly Arg Gly Asp Ser Pro 65 70 75 80 Ala Ser Ser Lys Pro Val Ser Ile
Asn Tyr Gln Thr 85 90 188 92 PRT Mus musculus 188 Val Ser Asp Ile
Pro Arg Asp Leu Glu Val Ile Ala Ser Thr Pro Thr 1 5 10 15 Ser Leu
Leu Ile Ser Trp Glu Pro Ala Val Ser Val Arg Tyr Tyr Arg 20 25 30
Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Pro Val Gln Glu Phe Thr 35
40 45 Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Asn Ile Lys Pro Gly
Ala 50 55 60 Asp Tyr Thr Ile Thr Leu Tyr Ala Val Thr Gly Arg Gly
Asp Ser Pro 65 70 75 80 Ala Ser Ser Lys Pro Val Ser Ile Asn Tyr Lys
Thr 85 90 189 40 PRT Oryctolagus cuniculuc VARIANT 24 Xaa = Any
Amino Acid 189 Val Ser Asp Val Pro Arg Asp Leu Glu Val Ile Ala Ser
Thr Pro Thr 1 5 10 15 Ser Leu Leu Ile Ser Trp Glu Xaa Pro Ala Val
Thr Val Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Gly Glu Thr Asn 35 40
190 92 PRT Gallus gallus 190 Val Ser Asp Val Pro Arg Asp Leu Glu
Val Asn Thr Ser Pro Thr Ser 1 5 10 15 Leu Glu Ile Ser Trp Asp Ala
Pro Ala Val Thr Val Arg Tyr Tyr Arg 20 25 30 Ile Thr Tyr Gly Glu
Thr Gly Gly Ser Ser Pro Val Gln Glu Phe Thr 35 40 45 Val Pro Gly
Thr Met Ser Ala Thr Ile Thr Gly Leu Lys Pro Gly Val 50 55 60 Asp
Tyr Thr Ile Thr Val Tyr Ala Val Thr Gly Arg Gly Asp Ser Pro 65 70
75 80 Ala Ser Ser Lys Pro Val Thr Val Thr Tyr Lys Thr 85 90 191 93
PRT Xenupus laevis 191 Val Ser Asp Val Pro Thr Asp Leu Glu Val Thr
Ser Ser Ser Pro Asn 1 5 10 15 Thr Leu Thr Ile Ser Trp Glu Ala Pro
Ala Val Ser Val Arg Tyr Tyr 20 25 30 Arg Ile Thr Tyr Ser Gln Thr
Gly Gly Gly Pro Glu Lys Glu Phe Thr 35 40 45 Val Pro Gly Thr Ser
Asn Thr Ala Thr Ile Arg Gly Leu Asn Pro Gly 50 55 60 Val Ser Tyr
Thr Ile Thr Val Tyr Ala Val Thr Gly Arg Gly Asp Ser 65 70 75 80 Pro
Ala Ser Ser Lys Pro Leu Thr Ile Ile His Lys Thr 85 90 192 68 PRT
Canis familiaris 192 Ala Asp Ala Pro Ser Leu Phe Leu Ala Thr Thr
Pro Ser Leu Leu Val 1 5 10 15 Ser Trp Gln Pro Ala Ile Thr Gly Tyr
Ile Ile Lys Tyr Gly Ser Glu 20 25 30 Val Val Pro Gly Val Thr Ala
Thr Ile Thr Gly Leu Pro Gly Thr Glu 35 40 45 Tyr Thr Ile Gln Val
Ile Ala Leu Lys Asn Gln Lys Ser Leu Ile Gly 50 55 60 Lys Thr Glu
Leu 65 193 67 PRT Equus caballis 193 Ala Asp Ala Pro Ser Leu Phe
Leu Ala Thr Thr Pro Ser Leu Leu Ile 1 5 10 15 Ser Trp Gln Pro Ala
Ile Thr Gly Tyr Ile Ile Lys Tyr Gly Ser Glu 20 25 30 Val Val Pro
Gly Val Thr Ala Thr Ile Thr Gly Leu Pro Gly Thr Glu 35 40 45 Tyr
Thr Ile Gln Val Ile Ala Ile Lys Asn Gln Lys Ser Leu Ile Gly 50 55
60 Lys Thr Glu 65 194 70 PRT Homo sapiens 194 Val Ser Pro Pro Lys
Asp Leu Val Thr Val Thr Thr Val Asn Leu Ala 1 5 10 15 Trp Asp Met
Val Thr Tyr Leu Val Val Tyr Thr Pro Thr His Glu Gly 20 25 30 Gly
Glu Met Gln Phe Val Pro Gly Asp Gln Thr Ser Thr Ile Ile Gln 35 40
45 Leu Pro Gly Val Glu Tyr Phe Ile Arg Val Phe Ala Ile Leu Asn Lys
50 55 60 Lys Ser Val Ser Ala Val 65 70 195 69 PRT Sus scrofa 195
Val Ser Pro Pro Lys Asp Leu Val Thr Val Thr Thr Val Asn Leu Ala 1 5
10 15 Trp Asp Met Val Thr Tyr Leu Ile Val Tyr Thr Pro Thr His Glu
Gly 20 25 30 Glu Met Gln Phe Val Pro Gly Asp Gln Thr Ser Thr Thr
Ile Arg Leu 35 40 45 Pro Gly Val Glu Tyr Phe Ile Arg Val Phe Ala
Ile Leu Asn Lys Lys 50 55 60 Ser Val Ser Ala Val 65 196 75 PRT Mus
musculus 196 Met Asp Gly Pro Gln Asp Leu Val Val Ala Val Thr Pro
Thr Thr Leu 1 5 10 15 Asp Leu Ser Trp Pro Gln Ala Val Asp Phe Val
Val Ser Tyr Val Ser 20 25 30 Ala Gly Asn Arg Val Leu Val Pro Pro
Glu Ala Asp Thr Gln Leu Thr 35 40 45 Leu Met Pro Gly Val Glu Tyr
Val Val Thr Val Thr Ala Glu Arg Gly 50 55 60 His Ala Val Ser Ala
Ser Ile Ala Asn Thr Gly 65 70 75 197 69 PRT Homo sapiens 197 Thr
Val Pro Ser Leu Ile Tyr Val Gly Pro Thr Thr Met His Val Gln 1 5 10
15 Trp Gln Val Gly Gly Ala Thr Gly Tyr Ile Leu Ser Tyr Pro Val Asp
20 25 30 Thr Glu Thr Lys Glu Val Leu Gly Pro Thr Val Asn Met Gln
Leu Thr 35 40 45 Leu Val Pro Asn Thr Glu Tyr Ala Val Thr Val Gln
Ala Val Leu Leu 50 55 60 Thr Ser Val Thr Val 65 198 44 PRT
Oryctolagus cuniculus 198 Thr Val Pro Ser Leu Asn Ile Tyr Val Gly
Pro Thr Thr Met His Val 1 5 10 15 Gln Trp Gln Val Gly Gly Ala Thr
Gly Tyr Ile Leu Ser Tyr Pro Val 20 25 30 Asp Thr Glu Thr Lys Gln
Val Leu Arg Val Thr His 35 40 199 66 PRT Gallus gallus 199 Leu Ser
Asp Leu Leu Tyr Val Ser Ser Ser Met Arg Ala Lys Trp Gly 1 5 10 15
Val Ala Gly Ala Thr Gly Tyr Met Ile Leu Tyr Ala Pro Leu Thr Glu 20
25 30 Gly Leu Ala Ala Glu Lys Glu Ile Ile Gly Glu Ala Ser Thr Leu
Glu 35 40 45 Leu Asp Gly Leu Leu Pro Asn Thr Glu Tyr Thr Val Thr
Val Tyr Ala 50 55 60 Met Phe 65 200 72 PRT Homo sapiens 200 Leu Ser
Asp Leu Leu Tyr Val Thr Ser Met Arg Val Lys Trp Asp Ala 1 5 10 15
Val Gly Ala Ser Gly Tyr Leu Ile Leu Tyr Ala Pro Leu Thr Glu Gly 20
25 30 Leu Ala Gly Glu Lys Glu Met Ile Gly Glu Thr His Thr Ile Glu
Leu 35 40 45 Ser Gly Leu Leu Pro Asn Thr Glu Tyr Thr Val Thr Val
Tyr Ala Met 50 55 60 Phe Gly Ala Ser Asp Val Thr Gly 65 70 201 117
PRT Lama glama 201 Asp Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val
Gln Ala Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
Arg Thr Gly Ser Thr Tyr 20 25 30 Asp Met Gly Trp Phe Arg Gln Ala
Pro Gly Lys Glu Arg Glu Ser Val 35 40 45 Ala Ala Ile Asn Trp Asp
Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val 50 55 60 Arg Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr 65 70 75 80 Leu Gln
Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys 85 90 95
Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln 100
105 110 Val Thr Val Ser Ser 115 202 94 PRT Homo sapiens 202 Val Ser
Asp Val Pro Arg Asp Leu Glu Val Val Ala Ala Thr Pro Thr 1 5 10 15
Ser Leu Leu Phe Ser Trp Asp Ala Pro Ala Val Thr Val Arg Tyr Tyr 20
25 30 Arg Ile Thr Tyr Gly Glu Thr Gly Gly Asn Ser Leu Val Gln Glu
Phe 35 40 45 Thr Val Pro Gly Ser Lys Ser Thr Ala Thr Ile Ser Gly
Leu Lys Pro 50 55 60 Gly Val Asp Tyr Thr Ile Thr Gly Tyr Ala Val
Thr Gly Arg Gly Asp 65 70 75 80 Ser Pro Ala Ser Ser Lys Pro Ile Ser
Ile Asn Tyr Arg Thr 85 90
* * * * *